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Chlamydia trachomatis is a gram negative, obligate intracellular pathogen with a
highly reduced genome of ~1 Mbp. It is the leading cause of the reportable sexually
transmitted infection known as chlamydia in the United States and is the leading cause
of preventable blindness (trachoma) worldwide. While treatment of infections is
possible, weaknesses of current approaches include treatment failure, antibioticinduced dysbiosis, and resistance development of bystander bacteria during chlamydial
treatment. These weaknesses support the need for improved therapeutic approaches.
C. trachomatis undergoes a biphasic developmental cycle with two forms, the infectious
elementary body (EB) and replicative reticulate body (RB), that have unique protein
profiles. Due to the differing proteomes of each developmental form, we hypothesized
that mechanisms that facilitate protein turnover will be essential for progression of C.
trachomatis through the developmental cycle making them ideal drug targets. This study
focused on characterization of two caseinolytic protease (Clp) systems: the ClpX/P2/P1
system and the ClpC/P1/P2 / McsAB system. We predicted that ClpP1 and ClpP2 come
together to form the proteolytic component, that ClpX and ClpC are unfoldases that
unfold and linearize large substrates in an ATP dependent manner for ClpP-dependent
proteolysis, and that McsAB are adaptor proteins with McsA activating the kinase McsB
to tag proteins for degradation by the ClpC/P1/P2 complex. The Clp system has been
i

the focus of numerous studies as a target for novel antimicrobials and we hypothesized
that the chlamydial Clp system would also be a druggable target. To assess the
functionality of the Clp system, we successfully purified all components except McsB for
use in vitro assays. Using oligomerization, peptide and protein degradation assays, and
ATP hydrolysis assays, we characterized the activity of the ClpP1, ClpP2, and ClpX
components individually and in complexes. We also measured the activity of a collection
of ClpX mutants. In addition, we assessed the activity of ClpP-targeted activating
compounds that were potent in vivo inhibitors of C. trachomatis. We demonstrated that
ClpP2/P1 can form hetero-oligomers and degrade peptides and that ClpX has ATPase
activity, can oligomerize, and can degrade an SsrA-tagged GFP when complexed with
ClpP2/P1. While the activator studies did not support interactions with ClpP2/P1 under
the conditions tested, assays were developed for further analysis of Clp-targeted
compounds. Our in vitro results support that C. trachomatis possesses a functional Clp
system. In addition, in vivo expression of ClpX mutants confirmed to lack activity in our
in vitro assays led to reduced chlamydial fitness and alterations in development
supporting our hypothesis that the Clp system is required for chlamydial development.
Collectively, our results indicate that the Clp system is critical to C. trachomatis survival
in cells and suggests that drugs altering Clp-function could be a novel approach for antichlamydial therapeutics.
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CHAPTER 1
INTRODUCTION
Organism Overview
Members of the family Chlamydiaceae are gram negative obligate intracellular
bacteria characterized by a unique biphasic developmental cycle and reduced genome
(~1 Mbp) (1, 2). This family contains the genus Chlamydia, which encompasses
organisms responsible for a variety of serious diseases in both animals and humans. In
general, these pathogens infect epithelial cells lining mucosal tissue and elicit damage
through immunopathology. Many of the organisms in this genus are host restricted,
including Chlamydia suis (swine), Chlamydia muridarum (rodents of the family Muridae),
and Chlamydia caviae (guinea pigs) (1). However, other organisms within this genus
are able to infect a variety of hosts and even cause zoonotic infections in humans (3).
Chlamydia felis is endemic among household cats worldwide and Chlamydia abortus
commonly infects ruminants, but both are also able to cause zoonotic infections in
humans (1, 3). Of particular clinical importance to humans are the pathogens Chlamydia
pneumoniae, Chlamydia psittaci, and Chlamydia trachomatis. C. psittaci is a zoonotic
pathogen that is able to infect humans that come in contact with aerosolized bacteria
from the respiratory tract or fecal material from infected birds causing the disease
psittacosis (4). Although rare, failure to recognize the symptoms of psittacosis can result
in severe respiratory disease or even death (4). C. pneumoniae is known to cause
respiratory tract infections that can result in pneumonia and has also been implicated in
chronic inflammatory diseases such as atherosclerotic cardiovascular diseases,
Alzheimer’s disease, and reactive arthritis (5). C. trachomatis, the focus of my research,
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causes different forms of disease that have large public health implications, which are
highlighted in the following pathology section.
Chlamydia trachomatis Pathology
C. trachomatis has two different biovars: the oculogenital biovar with ocular tropic
(serovars A-C) and genitourinary tropic strains (serovars D-K) and the
lymphogranuloma venereum (LGV, serovars L1-L3) biovar which contains more
invasive strains (6, 7). Serovars A-C of the ocular pathotype cause chronic ocular
infections called trachoma that can lead to blindness (7). Trachoma is the leading cause
of preventable blindness affecting over 1.9 million people worldwide (8). Serovars D-K
of the genital pathotypes are responsible for the disease chlamydia, which is the leading
cause of reportable bacterial sexually transmitted infections (STIs) world-wide and can
infect the genital, oral, and rectal tissues (7). LGV serovars L1-L3 make up the minority
of reported STIs, but unlike serovars D-K they can cause an invasive and systemic
infection that moves from the initial site of infection to regional lymph nodes leading to
lymphadenopathy (9). A major concern with chlamydia is that up to 50% of STI cases in
men and up to 90% of cases in women can be asymptomatic resulting in failure to seek
treatment (10). In women, untreated infections can allow C. trachomatis to ascend the
reproductive tract and cause pelvic inﬂammatory disease, ectopic pregnancy, chronic
pelvic pain, or even infertility (10). Despite its largely asymptomatic nature, chlamydia is
the most commonly reported STI in the United States with 1.8 million reported cases in
2018 resulting in a national financial burden of over 600 million dollars (11). Despite the
increasing prevalence of bacterial resistance to antibiotics amongst many important
human pathogens, evidence of clinical resistance in Chlamydia isolates is rare with the
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only known resistance marker being a tetracycline efflux pump found in C. suis (12).
Consequently, human infections can still be treated using tetracyclines (doxycycline),
macrolides (azithromycin), and fluoroquinolones (13, 14). While resistance is not
currently a clinical problem, there are weaknesses to the available chlamydia
therapeutic approach: 1) treatment failure can occur in 5-23% of the population (14),
and 2) the frontline drugs doxycycline and azithromycin are broad-spectrum antibiotics
that induce dysbiosis of the host’s microbiome and increase the risk of resistance
development in other pathogens such as Neisseria gonorrhoeae (14-16). Novel,
Chlamydia-specific therapeutic targets could provide relief from treatment failure, druginduced dysbiosis, and non-chlamydial drug-resistance observed with current therapies.
Developmental Cycle
Chlamydia undergo a biphasic developmental cycle transitioning between the
infectious elementary body (EB) and the replicative reticulate body (RB) (fig. 1.1) (17).
Upon attachment to a mucosal epithelial cell, the EB is taken up into a host cell derived
vacuole via normal cellular endosomal-trafficking pathways (18). In a type III secretion
dependent manner, the EB will then transform its intracellular environment, known as
the inclusion, into a unique parasitophorous vacuole for two main reasons: 1) to avoid
normal trafficking through the host endocytic pathway so it is not degraded by
lysosomes and 2) to fulfill its nutritional needs via interaction with exocytic pathways
(17, 18). Within the inclusion, the small and compact EB (~0.3 µm in diameter)
transforms into the larger and less dense RB form (~0.9 µm) and around 12 hours postinfection will begin replication and cell division to produce more RBs (19). Two models
are proposed for how Chlamydia divide: 1) binary fission, or 2) a recently proposed
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budding model of division (19, 20). The RB then has two fates prior to commencing
conversion into an EB: continued growth and division or transition into the persistent
form. Persistence can result from unfavorable conditions within the host cell, such as in
the case of exposure to antibiotics, cytokines (i.e. interferon-γ), or a nutrient-deficient
environment including tryptophan or iron deprivation (21). If cellular conditions favorable
for bacterial growth and replication remain in place, or once unfavorable conditions have
subsided, the RBs will continue to grow and divide until 18-40 hours post-infection,
when the RB population will asynchronously differentiate into EBs (17, 19). Finally,
infectious EBs are released from the host cell to infect other host cells or new hosts
(17).
The two different developmental forms of Chlamydia are unique in both structure
and function. Structurally, EBs are only ~0.3 μm in diameter and have a rigid outer
membrane despite the presence of little to no peptidoglycan. The rigid structure is likely
due to highly cross-linked outer membrane protein complexes that are rich in cysteine
residues. The presence of multiple cysteines is significant as EBs are oxidized
compared to the RB form, which suggest that Chlamydia may use redox in conjunction
with protein cysteine content to both stabilize the bacterial envelope and as a regulatory
mechanism (22, 23). The EB form of Chlamydia is considered metabolically restricted
due to its DNA being highly compacted by the bacterial histone-like proteins HctA and
HctB hindering transcription and therefore translation. This developmental form of
Chlamydia has been likened to be the “spore-like” form of the species with minimal
energy processes maintained to support infection. The RB form is larger than an EB
with a diameter of ~0.9 μm. The membrane structure is not as rigid as EBs and RBs
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have the characteristic inner membrane and outer membrane as seen in other gram
negative bacteria. In contrast to typical gram negative bacteria, Chlamydia are
peptidoglycan-poor, with the cell wall localized to rings at the site of cell division (24).
The highly compacted DNA as seen in EBs is relaxed to allow for initiation of
transcription and translation allowing for metabolic and physiological processes in the
RBs that promote growth and division within the host cell. The distinct physiological
differences between the EB and RB forms are conferred by divergent protein profiles
between the two forms, which is supported by multiple proteomic studies (25-27). One
group that set out to examine the differing proteomic profiles of the two forms concluded
that the proteome of EBs is primed for generating bursts of energy via glucose
catabolism to fuel the developmental transition from EB to RB while the proteome of
RBs is specialized for robust protein synthesis, accumulation of ATP, and nutrient
transport (26). Antibiotics that target transcription and translation, such as doxycycline
and azithromycin, can block differentiation from EB to RB, suggesting that de novo
protein expression, synthesis, and subsequent homeostasis of these proteins is going to
be required for intracellular growth and continuation of the developmental cycle (28).
Clearly, protein turnover is essential for chlamydial development making the process an
ideal therapeutic target, but there is a significant gap in our knowledge of how the
proteome shifts are regulated and carried out.

5

Figure 1.1. The chlamydial developmental cycle.
Protein Homeostasis
Protein homeostasis, also referred to as proteostasis, is essential for bacteria to
survive in dynamic environments that support optimal growth or present stressors such
as temperature, osmotic shock, oxidation, immune factors, and toxics including
antibiotics (29, 30). Upon exiting the ribosome, the polypeptide is exposed to a highly
crowded cellular environment and it is essential that newly synthesized proteins are
able to fold into their functional, native state. If the protein is unable to fold unassisted,
then it will need the help of specialized proteins called chaperones (31, 32). Despite
extra help from chaperones, sometimes a nascent protein may find itself tangled in a
self-aggregate or with other proteins. In addition, proteins can become damaged
overtime, may lose their conformation due to environmental insults, or are no longer
6

needed due to physiological changes in the bacterium such as developmental changes
as observed for the chlamydial RB/EB. To deal with these “protein problems” bacteria
have a collection of chaperones that work independently or as complexes and are
generally assigned into three categories based on function (with some overlap between
them): folding, disaggregation, and degradation (fig. 1.2) (33).
The first type of proteins involved in protein homeostasis are those that perform
protein folding and/or refolding. A common chaperone system used for protein
(re)folding is the ATP-dependent GroEL/ES system (34, 35). The GroEL tetradecamer
has hydrophobic amino acids, which bind and capture non-native proteins that need to
be refolded. Upon association of the protein substrate with the GroEL barrel, the GroES
“cap” will associate with the complex and drive the protein substrate farther into GroEL.
Next, in an ATP-dependent manner, the protein is refolded and subsequently released
in its native form (35). Uniquely, Chlamydia have three GroEL homologs, but with only
one being essential for growth in cell culture and likely serving the role as the bona-fide
GroEL-GroES chaperone (36).
The second type of chaperones involved in proteostasis are those that resolve
aggregates. Aggregates typically arise from two scenarios. Under normal conditions,
some proteins may require molecular chaperones to complete folding, but if these
chaperones are not readily available, it can lead to the problematic presence of
unfolded proteins in the cytoplasm that interact to form aggregates. Alternatively, under
stressful conditions, a protein can lose its noncovalent interactions and have its
secondary and tertiary structures disrupted, leading to unfolding of the protein. Often
times, this loss of structure can cause the unfolded protein to assume a structure that
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deviates from its functional state through the formation of non-native interactions to form
aggregates (37). Protein aggregates can be cytotoxic to cells via trapping other cellular
proteins or by physically blocking cellular processes (38), so the cell needs to have
mechanisms to not only resolve aggregates, but also to prevent their formation. The
DnaJK/GrpE and ClpB bichaperone machinery is one example of molecular chaperones
working together to resolve protein aggregates. Within this system, small heat shock
proteins bind the proteins within the aggregate and maintain them in a near-native state
until displaced by DnaJ and DnaK. GrpE acts as a nucleotide exchange factor for DnaK,
swapping ADP for ATP following DnaK ATP hydrolysis. DnaK will then recruit the ClpB
disaggregase, which will activate its ATPase activity to extract substrates from the
aggregate where they can then be refolded (such as by the GroEL/ES system) or
degraded (37).
Before proteins are able to form these aggregates, bacteria can maintain a
functional proteome by tagging proteins directly for degradation. In the bacterial
periplasm, including Chlamydia is a protease designated as DegP. This protease
functions upon initiation of the bacterium’s heat shock response to degrade partially
folded proteins denatured by elevated temperatures. Additionally, DegP is able to act as
a “holding” chaperone to prevent the formation of aggregates within the periplasm (33,
39).
In the cytoplasm, bacteria can maintain functional proteomes by proteolytic
families such as the Lon proteases or the caseinolytic proteases (Clp) (fig. 1.3) (40).
Both of these degradation machineries fall into the AAA+ protein family (ATPases
associated with various cellular activities) due to their similar ATP-driven degradation
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mechanisms (40, 41). After binding of the substrate, the protease linearizes the target
through the use of ATP, enabling the unfolded substrate to be fed into the proteolytic
chamber and subsequently degraded (41). The Lon protease functions using a catalytic
dyad of serine and lysine with a hypothesized structure of a three-tiered hexagonal
cylinder (42-44). Unregulated protease activity is typically lethal for bacteria as seen
with the overexpression of the Lon protease in Escherichia coli (45). To avoid improper
protease activity, E. coli and other bacteria rely on the recognition of specific
degradation tags, known as degrons, to keep proteolysis in check. In addition to Lon
protease, the other cytoplasmic protease system commonly found in bacteria is the Clp
protease, which is the focus of this thesis.

Figure 1.2. Overview of the major proteostasis processes in bacteria. Used with
permission from Oxford University Press through Copyright Clearance Center’s
RightsLink® service (37).
9

Clp Proteases
The caseinolytic proteases (Clp) are a class of proteases that utilize a highly
conserved serine protease core, ClpP, in conjunction with various adaptor proteins. The
ClpP protease possesses a catalytic triad (active site) of a serine, histidine, and an
aspartic acid (46, 47). Structurally, ClpP orthologs are similar in that they form two
heptameric rings that come together to form the functional tetradecamer with each
monomer containing its own active site. Some bacteria, such as E. coli and Bacillus
subtilis, have homo-tetradecamers in which all of the monomers are from a single ClpP.
However other bacteria, such as Chlamydia, Mycobacterium tuberculosis, and
Pseudomonas aeruginosa, encode two orthologs of ClpP instead of one, so these
orthologs can form homo-heptamers (ClpP1 7 or ClpP27) that come together to form a
hetero-tetradecamer (ClpP17 plus ClpP27) (48, 49). The compartmentalized structure of
the tetradecamer effectively shields the active sites of ClpP from the cytoplasm so they
will not interact with unintended targets (50).
The ClpP complex itself is only able to degrade small substrates (<5 kDa),
however it is able to interact and degrade larger substrates with the help of AAA+
(ATPases associated with various cellular activities) unfoldases such as ClpX, ClpA,
and ClpC (51, 52). The unfoldases form homo-hexamers that interact with the ClpP
tetradecamer protease complex. The unfoldase, in an ATP-dependent manner,
recognizes the degron on a condemned protein, unfolds its tertiary structure, and
translocates the unfolded substrate into the ClpP barrel for degradation into peptide
fragments (53). Clp proteases have been shown to play essential roles in cells such as
removing damaged, denatured, and aberrantly folded proteins that are harmful to the
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cell and they are also important for bacterial virulence (52, 53). As such, efforts have
been made to develop drugs that target these systems as novel approaches for
treatment of bacterial infections. Typically, Clp-targeted drugs act as either inhibitors or
activators of the system. Inhibitors usually target unfoldases and inhibit the activity of it
so the system can no longer maintain homeostasis (54). Activators make the Clp
system hyperactive, such as increasing the size of the ClpP proteolytic barrel alleviating
the need for an unfoldase and leading to uncontrollably degradation of proteins within
the cell (55). Chlamydia encode two adaptors, ClpX and ClpC, and two proteases,
ClpP1 and ClpP2. We hypothesize that these systems are essential for chlamydial
development making them druggable targets. Furthermore, we hypothesize that a
ClpX/P2/P1 system is needed for trans-translation and cell division and that a
ClpC/P1/P2 / McsAB system is used to degrade phospho-arginine tagged proteins.

Figure 1.3. General structure and mechanism of Clp systems. ClpP can form
homomeric barrels or heteromeric barrels as pictured where yellow would be ClpP1 and
blue would be ClpP2.
11

ClpXP system
The ClpXP system can serve various functions in cells. A common function of the
ClpXP is degrading tagged proteins produced by trans-translation. Trans-translation
occurs when a ribosome is stalled on a transcript lacking a stop codon and in general
resolves mRNA problems in the cell (56). Ribosome stalling on damaged mRNA results
in partially translated peptides, which can present a potentially dangerous situation to
bacteria as these truncated products can have a dominant negative effect on growth in
addition to trapping ribosomes on non-productive transcripts (57). Before the ribosome
can be rescued, a hybrid RNA called the tmRNA binds to SmpB and becomes
aminoacylated by alanyl-tRNA synthetase. GTP-bound EF-Tu binds this charged
tmRNA so that it is ready to interact with the stalled ribosome. Once charged, this
tmRNA complex recognizes and binds to the 3’ end of the mRNA to enter the A-site of
the ribosome. Via transpeptidation, the truncated polypeptide transfers over to the
tmRNA. The tRNA that had the truncated polypeptide is displaced from the P site of the
ribosome utilizing the GTP from EF-TU so it can be replaced with the truncated
polypeptide now cross-linked to the tmRNA. The freed mRNA transcript that did not
contain a stop codon can then be degraded by RNases within the cell. Translation can
then resume using the tmRNA as a template, and this will result in addition of a Cterminal SsrA degradation tag. Once the stop codon within the tmRNA is reached, the
tagged protein and the ribosome are released, and the tagged protein is degraded by
targeted proteolysis via the Lon protease, Tsp protease, or the ClpXP system (fig. 1.4)
(56, 58).
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While degrading products of the trans-translation system is an important role of
the ClpXP complex, it is not the only role that it can serve. The N-terminus of ClpX
contains a zinc-binding domain (ZBD) important in binding adaptor proteins so that the
ClpX can be tailored to degrade other types of °proteins based on their degradation tag
(59, 60). In organisms with developmental forms such as Caulobacter, its essential
ClpXP system can be modulated by the addition of a number of adaptor proteins and
the more that bind, the narrower the specificity for substrates (61, 62). This
demonstrates the potential range in substrates that the ClpXP system can degrade. In
addition to the ZBD motif, Chlamydia’s ClpX contains other conserved motifs associated
with AAA+ unfoldases including the Walker A and Walker B motifs associated with ATP
binding and ATP hydrolysis respectively, the IGF loop important for ClpX binding to
ClpP, and the RKH motif associated with substrate recognition (specifically SsrA tag
recognition associated with trans-translation) (47, 53, 60). Mutation of these motifs can
alter ClpX function and inhibit chlamydial growth as demonstrated in vivo by our group,
in which an overexpressed ClpX Walker B motif mutant led to abnormal developmental
forms that appeared multinucleated and having abnormally condensed intermediate
forms (60). Further characterization of the ClpXP system in Chlamydia will be essential
to delineate its role(s) in chlamydial growth and for future studies aimed at developing
ClpX-targeted therapeutics.
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Figure 1.4. Process of trans-translation. Used with permission from Annual Review of
Microbiology through Copyright Clearance Center’s RightsLink® service (56).
McsAB and ClpCP System
The McsAB and ClpCP system, based on literature review, is almost exclusively
a gram positive system, except for Chlamydia which is gram negative. It is best
characterized in B. subtilis, where the McsAB and ClpCP system is involved in
degradation of phosphoarginine-tagged proteins. The ClpCP complex functions similarly
to the ClpXP in that ClpP serves as the proteolytic component and ClpC functions as
14

the unfoldase in an ATP-dependent manner (63). McsA is the activator of McsB, which
functions as an arginine kinase in B. subtilis. Under normal, non-stress inducing
conditions, ClpCP sequesters McsB rendering it inactive. Upon stress-inducing
conditions such as increased temperature, McsB will be released from ClpCP and
activated by McsA. In keeping with a heat-related stress response, the repressor CtsR
will dissociate from DNA and be phosphorylated on conserved arginine residues by the
activated McsB. The various arginine phosphorylation of CtsR by McsB prevents CtsR
from rebinding to its target DNA allowing for transcription of heat stress response genes
(64). McsB also serves as an adaptor protein, so it will deliver the argininephosphorylated CtsR to the ClpCP complex where it can be degraded. McsB can also
phosphorylate damaged proteins targeting them to ClpCP for degradation. To return the
McsB system back to the resting state in B. subtilis, one of two things can happen: 1)
the phosphatase YwlE can dephosphorylate McsB to return it to its inactive state or 2)
McsB can be degraded by the ClpCP complex (65). Interestingly, there is no annotated
homolog of the YwlE phosphatase found in Chlamydia. This could mean that the McsB
in Chlamydia is degraded once it is no longer needed, as is seen in B. subtilis. A second
potential solution is that the YwlE homolog escapes annotation as Chlamydia are
phylogenetically distinct from B. subtilis. Alternatively, since Chlamydia has a small
genome of only 1 Mbp, it is possible that an already annotated phosphatase in
Chlamydia also functions in dephosphorylating the system and returning it to a resting
state. Dual functionality of proteins within Chlamydia is a common theme. One example
is CppA, which is a PP2C-type phosphatase that can dephosphorylate P-serine, Pthreonine, and unexpectedly P-tyrosine (66). Another examples is the Npt1 ATP/ADP
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translocase which is also able to transport NAD+ (67). A fourth solution is that McsB will
function as both a kinase and its own phosphatase, such as seen in Geobacillus
stearothermophilus (68). Along with the chance of missing a YwlE, another missing
component of this system is the transcriptional regulator CtsR, although this is only one
target protein of the system and may simply reflect differing physiological needs
between Chlamydia and Bacillus. The exact function and mechanisms of action of the
McsAB and ClpC proteins in Chlamydia remain to be determined.
Statement of the Problem
Chlamydia is the most commonly reported bacterial STI in the United States and
its negative impact on both human health and healthcare costs are highly significant.
Chlamydia undergoes a biphasic developmental cycle alternating between two different
forms and the protein profiles between the two forms varies dramatically (26). We
hypothesize that the mechanisms that drive the differentiation of protein profiles, such
as protein degradation systems, are essential for Chlamydia’s progression through the
developmental cycle. The McsAB / ClpC/P1/P2 system and ClpX/P2/P1 systems of
Chlamydia are excellent candidates for both proteostasis and development, are largely
uncharacterized, and their actions represent a significant gap in our understanding of
basic chlamydial biology. Further understanding of these systems could provide new
therapeutic targets for improved treatment of chlamydial infections.
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CHAPTER 2
MATERIALS AND METHODS
Bacterial Culture Conditions
All strains constructed and used in this study are listed in Appendix A. E. coli
cloning strains DH5α and XL-1 blue (except those containing pHT08) and E. coli protein
production strain BL21 (DE3) were routinely grown and maintained using Luria-Bertani
(LB) broth and agar plates containing either 100 μg/mL ampicillin (Amp) or 20 μg/mL
chloramphenicol (Cm) as dictated by vector usage. E. coli cloning strains containing
pHT08 clones were grown and maintained on 2xYT broth and agar plates containing 50
μg/mL ampicillin. All E. coli BL21 (DE3) ΔPAX protein production clones (parent strain
provided by Dr. Peter Sass, University of Tuebingen) were grown using LB broth and
agar plates supplemented with 100 μg/mL ampicillin, 20 μg/mL chloramphenicol, and 50
μg/mL kanamycin (Kan). All B. subtilis clones were grown and maintained using 2xYT
media. B. subtilis clones with the vector pHT08 were grown in the presence of 5 μg/mL
chloramphenicol and if pHT08 was in a mutant B. subtilis (such as B. subtilis 168
ΔmcsA and B. subtilis 168 ΔmcsB), then kanamycin was also added to a final
concentration of 5 μg/mL.
Strain Construction
E. coli Strain Construction
Gene sequences were obtained from the NCBI database using genome
sequences for C. trachomatis 434/Bu (LGV serovar L2 strain, NC_010287.1), E. coli
K12 (NC_000913.3), or B. subtilis 168 (NC_000964.3). All clones containing either
pLATE31 or pLATE52 were generated using the Ligation Independent Cloning (LIC)
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method as directed (Thermo Scientific). Genes were amplified by PCR using Phusion
High-Fidelity PCR Master Mix with their respective primers (listed in Appendix C). Upon
amplification, products were run on an agarose gel, visualized using ethidium bromide
staining and UV transillumination, and then extracted and purified using the GeneJET
Gel Extraction Kit (Thermo Scientific). The PCR/pLATE product was then used for
chemical transformation into the respective E. coli cloning strain. Transformants were
subject to colony PCR using Fermentas Master Mix (Thermo Scientific) and the
respective primers (Appendix C) to confirm insertion of the gene into the vector. PCR
confirmed clones were struck out for isolation onto 100 μg/mL ampicillin LB plates,
grown in LB broth supplemented with ampicillin, and the plasmid isolated using the
GeneJET Plasmid Miniprep kit (Thermo Scientific). Upon sequence verification of the
insert (performed by Psomagen), plasmids were transformed via electroporation into
either E. coli BL21 (DE3) or E. coli BL21 (DE3) ΔPAX.
All clones containing pACYCDuet-1 were generated via restriction digestion of
the vector with either multiple cloning site (MCS) #1 using FastDigest Restriction
Enzymes BamHI and NotI or MCS#2 using FastDigest Restriction Enzymes NdeI and
XhoI (Thermo Scientific). Gene inserts were amplified by PCR using Phusion HighFidelity PCR Master Mix with their respective primers (listed in Appendix C). Upon
amplification, products were run on an agarose gel, and then extracted and purified
using GeneJET Gel Extraction Kit (Thermo Scientific). PCR products were digested with
the respective restriction enzymes and then cleaned up using the GeneJET PCR
Purification Kit. The digested PCR products and vector were ligated at a 3:1 free-ends
ratio overnight at 4C in T4 ligation buffer using T4 DNA ligase (Thermo Scientific). The
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next day, ligation reactions were chemically transformed into XL-1 Blue E. coli and
plated onto LB plates containing 20 μg/mL chloramphenicol. Transformants were
subject to colony PCR using Fermentas Master Mix (Thermo Scientific) and the
respective primers (Appendix C) to confirm insertion of the gene into the vector.
Confirmed clones were struck out for isolation and grown in LB broth containing
chloramphenicol so the plasmid could be isolated using the GeneJET Plasmid Miniprep
kit (Thermo Scientific). Upon sequence verification, clones that had only one gene insert
were transformed via electroporation into E. coli BL21 (DE3). For clones that were to
contain genes in both MCS#1 and MCS#2, the digestion process was repeated so the
other gene that was not already in the pACYCDuet-1 could be inserted. All clones were
sequence verified and transformed via electroporation into E. coli BL21 (DE3).
All clones containing pGex-6p-1 or pMAL-c5X were generated via restriction
digestion and insertion. Genes were amplified by PCR using Phusion High-Fidelity PCR
Master Mix with their respective primers (listed in Appendix C). Upon amplification,
products were run on an agarose gel, and then extracted and purified using GeneJET
Gel Extraction Kit (Thermo Scientific). For pGex-6p-1 clones, the vector and PCR
products were digested at 37C for 1 hour using the FastDigest Restriction Enzymes
BamHI and XhoI (Thermo Scientific). For clones containing pMAL-c5X, DNA was
digested at 37C for 1 hour using the FastDigest Restriction Enzymes BamHI and NotI
(Thermo Scientific). Digested PCR products were cleaned up using the GeneJET PCR
Purification Kit and vectors were agarose gel purified and isolated with the GeneJET
Gel Extraction Kit (Thermo Scientific). The digested PCR products and vector were
ligated at a 3:1 free-ends ratio overnight at 4C in T4 ligation buffer using T4 ligase
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(Thermo Scientific). The next day, ligation reactions were chemically transformed into E.
coli XL-1 and plated onto LB plates with 100 µg/mL ampicillin. Transformants were
subject to colony PCR using Fermentas Master Mix (Thermo Scientific) to confirm
insertion of the gene into the vector. Confirmed clones were struck out for isolation and
grown in broth culture so the plasmid could be isolated using the GeneJET Plasmid
Miniprep kit (Thermo Scientific). All clones were sequence verified and then transformed
via electroporation into E. coli BL21 (DE3) ΔPAX.
All pHT08 clones were generated via restriction digestion and insertion. Genes
were amplified by PCR using Phusion High-Fidelity PCR Master Mix with their
respective primers (listed in Appendix C). Upon amplification, products were run on an
agarose gel, and then extracted and purified using the GeneJET Gel Extraction Kit
(Thermo Scientific). The entire reaction mixture was then digested at 37C for 1 hour
using the FastDigest Restriction Enzymes BamHI and SmaI (Thermo Scientific).
Digested products were cleaned up using the GeneJET PCR Purification Kit. The
pHT08 vector was also digested at 37C for 1 hour using the same restriction enzymes,
incubated for an additional 15 minutes at 37C upon addition of FastAP (Thermo
Scientific), and then the product was isolated following extraction from the agarose gel.
The digested PCR products and vector were ligated at a 3:1 free-ends ratio overnight at
4C in T4 ligation buffer using T4 DNA ligase (Thermo Scientific). The next day, ligation
reactions were chemically transformed into DH5α E. coli and plated onto 2xYT plates
containing 50 mg/mL ampicillin. Transformants were subject to colony PCR using
Fermentas Master Mix (Thermo Scientific) to confirm insertion of the gene into the
vector. Confirmed clones were struck out for isolation and grown in broth culture so the
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plasmid could be isolated using the GeneJET Plasmid Miniprep kit (Thermo Scientific).
Upon sequence verification, plasmids were transformed via either electroporation or
natural competence into the respective B. subtilis strains.
Bacillus subtilis Transformation via Electroporation
Strains were grown in 5 mL of 2xYT media and appropriate antibiotics when
necessary at 37°C with vigorous shaking overnight. The next day, 500 μL of the
overnight cultures were transferred to 50 mL of 2xYT media and grown with shaking at
37°C until an OD600 of 0.2 was achieved. The culture was then supplemented with 1%
w/v DL-threonine, 2% w/v glycine, 0.1% w/v tryptophan and 0.03% v/v Tween 80
prepared in 2xYT and allowed to continue shaking at 200 rpm for an additional hour at
37°C. The culture was cooled on ice for 20 minutes and then spun down at 5000 x g for
10 minutes at 4°C. The pellet was washed twice with 10 mL of electroporation buffer (all
buffers and their components are listed in Appendix B) with the final pellet being
resuspended in 100 μL of electroporation buffer. One μg of the desired plasmid was
added to the final resuspension mixture and transferred to an ice-cold 2 mm cuvette.
The cells were shocked using the BioRad GenePulser Xcell at 2500 V, 200 Ω, and 25
μF and immediately transferred to 1 mL of 2xYT media supplemented with 0.5 M
sorbitol and 0.38 M mannitol. The culture was recovered at 37°C for 3 hours with
shaking at 100 rpm. The entire culture was then spun down and all but 100 μL of
supernatant removed. The pellet was resuspended in the remaining supernatant, plated
onto selective media, and incubated at 37°C overnight.

21

Bacillus subtilis Transformation via Natural Competence
To prepare competent B. subtilis cells, an overnight culture of recipient cells was
incubated at 37°C under vigorous agitation in 5 mL of HS medium. 50 mL of HS
medium was inoculated to an OD600nm of 0.05 using the overnight culture and then
incubated under vigorous shaking at 37°C. The growth curve was recorded every 30
minutes and immediately upon transition from exponential to stationary phase (OD 600nm
~ 1), 10 mL samples were taken every 15 minutes for a total of 4 samples. One mL of
sterile 87% v/v glycerol was added to each sample, mixed, and left on ice for 15
minutes. After the 15 minutes, samples were fractionated into 1 mL aliquots, snap
frozen in liquid nitrogen, and stored at -80°C. The next day, an aliquot was thawed at
37°C and used to inoculate 20 mL LS medium. Cells were than shaken slowly in a 30°C
water bath for 2 hours to obtain maximal competence. After 2 hours, 1 mL aliquots were
transferred to plastic reaction tubes (Caplugs Evergreen sterile 5 mL polystyrene test
tubes) containing 10 μL of 0.1 M EGTA (pH 7.2) and incubated at room temperature for
5 minutes. One μg of plasmid was added and the reaction mixture was incubated for 2
hours at 37°C with vigorous shaking. After 2 hours, the reaction mixture was spun down
at 5,000xg for 3 minutes, all but 100 μL of supernatant was removed, the pellet was
resuspended in the remaining supernatant, plated onto selective 2xYT medium
containing 5 μg/μL of chloramphenicol, and finally incubated at 37°C overnight.
Bacillus subtilis Colony PCR
A single colony was resuspended in elution buffer (10 mM Tris-HCl, pH 8.5) from
the Thermo Scientific GeneJET Plasmid Miniprep Kit in a 1.5 mL Eppendorf tube. The
tube was wrapped with parafilm and a hole was made in the top to allow for ventilation.
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The tube was then incubated for 5 minutes on ice followed by microwaving for 1 minute
and then immediately returned to ice for 30 seconds. This was repeated for a total of
three times in the microwave. Following the final microwave step, the tubes were
incubated on ice for 5 minutes. Samples were spun down at 5000 x g for 5 minutes at
4°C so that 1 μL of the supernatant could be used immediately in the PCR reaction.
Codon Optimization
DNA sequences for C. trachomatis 434/Bu McsA and McsB were obtained from
the National Center for Biotechnology Information (NCBI) database and entered into
codon optimization tools offered by both NovoPro and Integrated DNA Technologies
(IDT). NovoPro generated graphs to show improvement in codon selection compared to
the targeted expression system preferred codon usage (E. coli or B. subtilis). The
optimized IDT sequences were also entered into the NovoPro optimization tool to
assess improvement of the IDT optimized sequence and a double optimized sequence.
NovoPro, IDT, and double optimized sequences were compared and codons that fell
well below 20% of relative adaptiveness were replaced with codons that had a higher
percent of relative adaptiveness as determined by NovoPro. After codon optimization,
gBlocks were ordered from IDT and cloned into pHT08 or pLATE52 as previously
described.
Confirmation of Protein Production
Bacillus subtilis SDS-PAGE Protein Sample Preparation
One mL of B. subtilis culture was resuspended in 100 μL of B. subtilis SDS Lysis
Buffer and 3 μL of 50 mg/mL lysozyme was added. The sample was incubated at 37°C
for 5 minutes. Twenty-five μL of B. subtilis 5X SDS Sample Buffer was added and mixed
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well. The sample was heated at 95°C for 5 minutes. The sample was then centrifuged at
13,000 x g for 2 minutes and 10 μL of the supernatant was loaded onto SDS-PAGE
gels.
Urea Denaturing Purification
C-terminal 8xHis-tagged Bs McsA and McsB, codon optimized gBlock Ct McsA
and McsB, and N-terminal 6xHis-tagged codon optimized gBlock Ct McsB were purified
from a 15 mL culture of either Bs ΔA (Bs McsA and Ct McsA), Bs ΔB (Bs McsB and
8xHis-tagged Ct McsB), or E. coli BL21(DE3) ΔPAX (6xHis-tagged Ct McsB). Cultures
were induced for 2.5 hours at 37C with 1 mM IPTG. After induction, cultures were
pelleted by centrifugation and stored at -80C overnight. The next day, pellets were
resuspended in urea lysis buffer, sonicated, pelleted, and the supernatant was
transferred to prepared HisPur Cobalt Resin and rotated end over end for 30 minutes.
HisPur Cobalt Resin (Thermo Scientific) was prepared by washing it twice in 150 μL of
urea lysis buffer. The proteins were then washed 3x with urea lysis buffer and eluted
four times using urea elution buffer. Samples taken throughout the purification were
then mixed with Laemmli buffer with BME and run on 12% SDS-PAGE gels and protein
was detected using Coomassie Brilliant Blue Brilliant Blue Brilliant Blue staining. Note
that urea treated samples were not heated prior to gel analysis. Images were acquired
using a BioRad ChemiDoc MP Imaging System.
E. coli Protein Induction and Solubility Trials
Proteins expressed in E. coli were confirmed by western blot. Proteins were then
tested for optimal solubility by altering three variables: isopropyl β-D-1thiogalactopyranoside (IPTG) concentration, induction time, and induction temperature.
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Strains to be tested were grown in 50 mL of the respective media and supplemented
with appropriate antibiotics. Upon reaching OD600nm between 0.6 and 0.8, cultures were
induced with varying amounts of IPTG and subject to different incubation times and
temperatures. Upon completion of the experimental induction conditions, cultures were
split into 15 mL aliquots, spun down, and store at -80C overnight. The next day, pellets
were resuspended in 3 mL of the experimental lysis buffers and sonicated. Preinduction, post-induction, non-soluble (pellet), and soluble (supernatant) samples were
mixed with Laemmli containing BME, heated, and run on SDS-PAGE gels. Protein was
detected using Coomassie Brilliant Blue Brilliant Blue Brilliant Blue staining.
Bacillus subtilis Induction Trials
Proteins expressed in B. subtilis were also tested for optimal solubility using
three variables: isopropyl β-D-1-thiogalactopyranoside (IPTG) concentration, induction
time, and induction temperature. Strains to be tested were grown in 50 mL of the
respective media supplemented with appropriate antibiotics. Upon reaching OD 600nm
between 0.6 and 0.8, cultures were induced with varying amounts of IPTG and subject
to different incubation times and temperatures. After induction, cultures were split into
15 mL aliquots, spun down, and suspended in 300 μL of urea lysis buffer. Samples
were then sonicated, spun down, and the supernatant was transferred to 30 μL of preequilibrated HisPur Cobalt Resin. The resin and supernatant were mixed end over end
for 30 minutes to allow protein binding. After 30 minutes, the resin was spun down and
the supernatant was removed. The resin was washed twice with 60 μL of urea lysis
buffer, resuspended in Laemmli with BME, and stored at -20°C until samples were
assessed on 12% SDS-PAGE gels.
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Protein Purification
Puriﬁcation of recombinant wild-type and mutant ClpP proteins
C-terminal 6xHis-tagged C. trachomatis ClpP1, C. trachomatis ClpP2, and E. coli
ClpP were purified from 500 mL cultures of E. coli BL21(DE3) ΔPAX containing the
respective plasmids as described in Seleem et al. (55). Briefly, cultures were induced
for 20 hours at 18C with 0.5 mM IPTG. After induction, cultures were pelleted and
stored at -80C overnight. Samples were suspended in ClpP lysis / wash buffer,
sonicated, spun down to separate the nonsoluble and soluble fractions, filtered using
0.45 μm filters, and rotated end over end for 1 hour with HisPur Cobalt Resin (Thermo
Scientific). After binding, the resin was washed using the ClpP lysis / wash buffer to
remove contaminating proteins. Proteins were then eluted from the resin using the ClpP
elution buffer and collected. After four elution steps, the buffer was exchanged to ClpP
storage buffer using a Millipore Amicon Ultra 15 filtration units (3 kDa cut-off). ClpP
proteins were then quantified using the Bio-Rad Protein assay, assessed for purity on
12% SDS-PAGE gels with Coomassie Brilliant Blue staining, and identified using antiHis-tag western blot. Blotting was performed using a mouse monoclonal anti-6xHis
antibody (1:1000; Millipore HIS.H8) and a goat anti-mouse IgG HRP conjugated
secondary antibody (1:2000). Protein samples were aliquoted and stored at -80°C.
Purification of Recombinant ClpX:
C-terminal 6xHis-tagged C. trachomatis ClpX and ClpX mutants were purified
from 500 mL cultures of E. coli BL21(DE3) ΔPAX containing the respective plasmids as
described in Wood et al. (60). Briefly, cultures were induced for 20 hours at 18C with
0.5 mM IPTG. After induction, cultures were pelleted and stored at -80C overnight.
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Samples were suspended in ClpX lysis / wash buffer, sonicated, spun down to separate
the nonsoluble and soluble fractions, filtered using 0.45 μm filters, and rotated end over
end for 1 hour with HisPur Cobalt Resin (Thermo Scientific). After binding, the resin was
washed using the ClpX lysis / wash buffer to remove contaminating proteins. Proteins
were then eluted from the resin using the ClpX elution buffer and collected. After four
elution steps, the buffer was exchanged to ATPase assay buffer using a Millipore
Amicon Ultra 15 filtration units (3 kDa cut-off). ClpX proteins were then quantified using
the BioRad Protein assay, assessed for purity on 10% SDS-PAGE gels with Coomassie
Brilliant Blue staining, and identified using anti-His-tag western blot. Blotting was
performed using a mouse monoclonal anti-6xHis antibody (1:1000; Millipore HIS.H8)
and a goat anti-mouse IgG HRP conjugated secondary antibody (1:2000). Protein
samples were aliquoted and stored at -80°C.
Purification of Recombinant GFP
N-terminal 6xHis-tagged GFP was purified from a 500 mL culture of E. coli BL21
(DE3) ΔPAX containing the respective plasmids. Cultures were induced for 6 hours at
room temperature with 0.5 mM IPTG. After induction, cultures were pelleted and stored
at -80C overnight. Samples were resuspended in GFP lysis buffer, sonicated, spun
down to separate the nonsoluble and soluble fractions, filtered using 0.45 μm filters, and
rotated end over end for 1 hour with HisPur Cobalt Resin (Thermo Scientific). After
binding, the resin was washed using the GFP wash buffer to remove contaminating
proteins. Proteins were then eluted from the resin using the GFP elution buffer and
collected. After four elution steps, the buffer was exchanged to GFP storage buffer
using a Millipore Amicon Ultra 15 filtration units (3 kDa cut-off). GFP proteins were then
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quantified using the BioRad Protein assay, assessed for purity on 12% SDS-PAGE gels
with Coomassie Brilliant Blue staining, and identified using anti-His-tag western blot.
Blotting was performed using a mouse monoclonal anti-6xHis antibody (1:1000;
Millipore HIS.H8) and a goat anti-mouse IgG HRP conjugated secondary antibody
(1:2000). Fluorescence was confirmed by spotting samples on slides for fluorescence
microscopy and in 96 well plates for analysis with a BioTek Synergy H1 plate reader at
excitation λ = 465 nm and emission λ = 535 nm. Protein samples were aliquoted and
stored at -80°C.
Purification of pACYCDuet-1 His-tagged McsA
N-terminal 6xHis-tagged Ct McsA was purified from a 50 mL culture of E. coli
BL21(DE3). The culture was induced for 10 hours at 37°C with 1 mM IPTG. After
induction, the culture was pelleted and stored at -80C overnight. The pellet was
suspended in pACYCDuet-1 McsA lysis buffer, sonicated, spun down to separate the
nonsoluble and soluble fractions, filtered using 0.45 μm filters, and rotated end over end
for 1 hour with HisPur Cobalt Resin (Thermo Scientific). After binding, the resin was
washed using the pACYCDuet-1 McsA wash buffer to remove contaminating proteins.
Proteins were then eluted from the resin using the pACYCDuet-1 McsA elution buffer
and collected. After four elution steps, the buffer was exchanged to pACYCDuet-1 McsA
storage buffer using a Millipore Amicon Ultra 15 filtration unit (3 kDa cut-off). The
pACYCDuet-1 McsA protein sample was then quantified using the BioRad Protein
assay and assessed for purity on 12% SDS-PAGE gels with Coomassie Brilliant Blue
staining. Protein samples were aliquoted and stored at -80°C.
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Purification of MBP-tagged McsA
N-terminal MBP-tagged C. trachomatis McsA was purified from a 500 mL culture
of E. coli BL21 (DE3) ΔPAX. Cultures were induced for 2.5 hours at 37C with 1 mM
IPTG. After induction, cultures were pelleted and stored at -80C overnight. Samples
were suspended in McsA lysis buffer, sonicated, spun down to separate the nonsoluble
and soluble fractions, filtered using 0.45 μm filters, and rotated end over end for 1 hour
with Amylose Resin (New England BioLabs). After binding, the resin was washed using
the McsA wash buffer to remove contaminating proteins. Proteins were then eluted from
the resin using the McsA elution buffer and collected. After four elution steps, the buffer
was exchanged to McsA storage buffer using a Millipore Amicon Ultra 15 filtration units
(3 kDa cut-off). McsA proteins were then quantified using the BioRad Protein assay and
assessed for purity on 10% SDS-PAGE gels with Coomassie Brilliant Blue staining.
Pilot MBP-Tag Cleavage Trials for pMAL-c5X McsA
Thirty μg of purified MBP-tagged McsA was diluted to 100 μL in cleavage buffer.
Prior to addition of 0.6 μL of 1 mg/mL Factor Xa (New England BioLabs), 5 μL was
taken from the protein sample to serve as the uncut control. Once the Factor Xa was
added, the solution was split evenly so one could incubate at room temperature while
the other incubated at 4°C. Samples were mixed once every hour and 5 μL samples
were taken every 4, 7, and 24 hours. Samples were mixed with Laemmli with BME and
heated so they could be assessed on 10% SDS-PAGE.
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Clp Activity Assays
Fluorescent Peptide Degradation Assay
3 μM (monomeric concentration) of the Ct ClpP proteins were added to either
buffer E or buffer F and incubated for 1 hour at 37°C as reported in Wood et al. (55).
Upon addition of 500 μM Suc-Luc-Tyr-AMC (Boston Biochem) to give a final reaction
volume of 50 μL, fluorescence due to peptide degradation was measured every 5
minutes for 6 hours at 37°C using a BioTek Synergy HT plate reader set at an excitation
of 340/360 and an emission of 440/460.
FITC-casein Degradation Assay
Prior to use in assays, the FITC-labeled casein (Sigma-Aldrich C0528) was
resuspended in buffer PZ to a stock concentration of 200 μM. To remove free FITC, the
stock was passed through a Zeba 7K cutoﬀ spin columns (Thermo Scientiﬁc) calibrated
with ultrapure water and stored at 4°C. One or 0.1 μM (compound 40 only) of E. coli
ClpP or 6 μM Ct ClpP1 and ClpP2 was incubated with 25 μg/μL compounds (provided
by Dr. Martin Conda-Sheridan, UNMC) or DMSO solvent at 32°C for 30 min before
adding FITC-casein. Upon addition of 20 μM FITC-casein to give a final reaction volume
of 100 μL, the fluorescence resulting from FITC-casein degradation was measured for 3
hours with readings every 3 minutes at 32°C.
Kinase-GLO ATPase Assay for ClpX
Recombinant ClpX or mutant ClpX (1.5 μg) was incubated in up to 49.5 μL of
ATPase assay buffer without ATP for 10 minutes at room temperature. To initiate the
reaction, 1 μM of ATP dissolved in ATPase assay buffer was added to the reaction to
give a final volume of 50 μL and incubated at 30C for 1.5 hours. After the 1.5 hours, the
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reactions were incubated for an additional 30 minutes at room temperature. Fifty μL of
Kinase-Glo® reagent (Promega) was added to the reaction and it was incubated for 10
minutes at room temperature. Using a BioTek Synergy H1 plate reader, the
luminescence of the reaction was measured (ATP not consumed by ClpX).
Malachite Green BioMol ATPase Assay for ClpX
Recombinant ClpX or mutant ClpX (1.5 ug) was incubated in up to 49 µL ATPase
assay buffer without ATP for 10 minutes at RT. Upon addition of 1 mM ATP to give a 50
μL final reaction volume, the reaction was incubated for 2 hours at 32C. After 2 hours,
200 μL of BioMol Green reagent (Enzo) was added to each reaction and then allowed to
incubate for 20 minutes at RT. Inorganic phosphate released from ATP was
colorimetrically quantified at OD620nm using a BioTek Synergy H1 plate reader.
ClpX Oligomerization Native PAGE
Five ug of purified protein was incubated with oligomerization buffer at 37C for
20 minutes. After 20 minutes, the reaction was mixed with 5X native sample buffer
without heating and run on a BioRad MiniProtean 4-20% gradient gel for Native-PAGE.
Protein was detected using Coomassie Brilliant Blue staining.
GFP Degradation Assay
ClpP1 and ClpP2 at 3.5 μM and 3 μM of ClpX were incubated with 4 mM ATP, 8
mM creatine-phosphate, 10X buffer PZ, and 1 U/mL creatine phosphokinase for 30
minutes at 32C. GFP at 0.36 μM was then added to the reaction for a final volume of
100 μL, samples were mixed via pipetting, and fluorescence was read using a prewarmed (32C) BioTek Synergy H1 plate reader for 2 hours at excitation λ = 465 nm
and emission λ = 535 nm using a flat bottom white plate.
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Bacillus subtilis Thermotolerance Assay
The OD600nm was measured for 5 mL 2xYT overnight cultures of mcsA/B strains
grown at 37°C with 5 μg/mL chloramphenicol and kanamycin. Culture OD’s were then
standardized to 0.05 with fresh 2xYT broth containing 5 μg/mL chloramphenicol. Final
volumes were 50 mL. If necessary, 0.2 mM IPTG was added to induce mcsA/B gene
expression from the pHT08 vector. Cultures were then grown with shaking for eight
hours in a 53°C water bath with OD600nm readings taken every hour to track bacterial
growth.
Statistics and Replicates
In general, all protein assays were performed using at least two independent
protein purifications and assays were performed at least three times with replicates
used for each individual assay. Data are reported with error as standard deviation or
standard error, assay dependent. Statistics were calculated using GraphPad (Prism)
and one-way ANOVA analysis using Tukey “honestly significant difference” test with a p
< 0.05 considered significant.
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CHAPTER 3
RESULTS
Chlamydia Clp Proteins and Gene Organization
Figure 3.1A depicts the gene organization for the chlamydial Clp system
components based on annotated C. trachomatis genomes. In a prior study, we
demonstrated that all components of the Clp systems in Chlamydia are expressed as
RB-specific gene products and that the proteins could also be detected during the RB
stage, supporting that the genes are functional and that the proteins could impact the
developmental cycle (40). Due to clpP2 and clpX being present in the same operon, we
proposed a model of the chlamydial Clp system (fig. 3.1B) with the adaptor ClpX binding
to and interacting with the ClpP complex via the ClpP2 interface. This model is
supported by experiments done by Pan et al. in which they mutated the hydrophobic
pockets of ClpP1 and ClpP2 by which the ClpX would interact to form the protease
complex (48). The mutation in ClpP2, but not ClpP1, affected protease activity of the
ClpX/P2/P1 complex. In addition, the Pan et al. report found that ClpP2 and ClpP1 each
form homo-heptamers that then associate as a hetero-complex. Since ClpX
demonstrates preferential interaction with ClpP2, we hypothesize that the ClpC adaptor
protein will interact with the ClpP1 interface (fig. 3.1B).
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Figure 3.1. Gene organization and current model of the ClpX/P2/P1 and ClpC/P1/P2/
McsAB complexes. (A) Gene maps were generated using stdgen.northwestern.edu.
Red boxes highlight the clp genes and grey boxes denote putative promoters (40). (B)
The ClpX adaptor works with the ClpP2 interface of the ClpP2/P1 complex. Adaptor
proteins may bind to ClpX to help facilitate degradation of differentially tagged
substrates. The ClpC adaptor is hypothesized to work with the ClpP1 interface of the
ClpP2/P1 complex. In its inactive state, we predict McsAB will bind to the complex via
ClpC interaction.
To test our hypotheses regarding Clp complex structure and function(s) during
chlamydial growth and development, we took a two pronged-approach with our lab
focusing on in vitro characterization of the Clp proteins and the Scot Ouellette lab (with
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PhD student Nicholas Wood) at the University of Nebraska Medical Center leading the
in vivo aspects of the project. In general, in vivo results and their correlation with in vitro
results will be reserved for the Discussion. To facilitate our in vitro studies, we needed
to purify the Clp proteins along with protein substrates. The obligatory lifestyle of C.
trachomatis and the difficulty in genetically manipulating it led us to use E. coli and B.
subtilis as surrogate systems for protein production and purification. To assist in protein
purification, we took a recombinant gene approach that used different affinity tags to aid
in both protein solubility and purification. For the Clp proteins (Ct P1/P2/X/C, Ec P), Cterminal 6xHis tags were used (pLATE31, all constructs can be found in Appendix A)
consistent with prior literature on Clp homologs supporting that the modification was not
detrimental to oligomerization or protein function. Since the GFP construct carried a Cterminal ClpX degron tag, an N-terminal 6xHis tag (pLATE52) was used. All
recombinant Clp proteins and substrates were expressed in an E. coli ΔclpPAX mutant
to avoid contamination of protein preparations with the E. coli Clp homologs. The 6xHistagged proteins were purified via immobilized metal affinity chromatography (IMAC) on
HisPur Cobalt Resin. Proteins were concentrated and stored in their respective storage
buffer at -80°C, quantified using the Bradford assay, and 1 μg of each protein was
assessed for purity on SDS-PAGE (fig. 3.2).
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Figure 3.2. Assessment of protein purity. One µg of protein was run on SDS-PAGE gels
under reducing conditions and protein was detected with Coomassie Brilliant Blue
staining. The molecular weight ladder is on the left of each gel. Expected sizes in kDa
are as follows: ClpP1 is 21 kDa, ClpP2 is 22 kDa, ClpPec is 23 kDa, ClpXwt and all
ClpX mutants (except ClpXΔ1-64) are 47 kDa, ClpXΔ1-64 is 40 kDa, ClpC is 95 kDa,
and GFP is 32 kDa.
In Vitro Studies of the ClpXP System
Confirmation of Protein Activity
With purified protein in-hand, we then used a number of assays to study the
functions of the ClpXP components including fluorescent peptide and casein assays (for
ClpP1/P2 protease activity), an oligomerization assay (ClpP1/P2/X), an ATPase assay
(ClpX activity), and the GFP degradation assay (ClpX/P2/P1 activity). To assess ClpP1
and ClpP2 protease activity, the proteins were mixed and protease activity tested using
the well-established Suc-Luc-Tyr-AMC fluorescent peptide degradation assay (fig. 3.3).
While ClpP cannot degrade complex substrates without an adaptor, the protease can
typically accommodate small peptides within the protease opening leading to
degradation. ClpP1 and ClpP2 were incubated without the fluorescent peptide for one
hour at 37°C to promote oligomerization. Upon addition of the fluorescent peptide,
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fluorescence due to peptide degradation was measured. If the proteins were active,
then an increase in fluorescence should be detected upon cleavage of the peptide
which relieves quenching of the AMC fluorophore. ClpP from E. coli served as a positive
control.
The Ec ClpP had activity measuring over 150 RFU/min (fig. 3.3A and C). Ct
ClpP1/ClpP2 together had low level activity measuring at around 0.3 RFU/min.
However, when sodium citrate was added to the reaction, the activity of the
ClpP1/ClpP2 complex increased almost six-fold (fig. 3.3B and D). Some salts, such as
citrate, cause a “salting-out” effect that helps stabilize multimeric complexes which
subsequently leads to increased activity in the case of ClpP. Therefore, this assay was
successful in demonstrating the protease activity of the Ct ClpP1 and ClpP2 hetercomplex. In these assays, we did not detect activity when only Ct ClpP1 or Ct ClpP2
were used (data not shown). Since we also planned to test the affect of various
compounds on ClpP acitivity, we measured the impact of DMSO, used as a solvent for
the compounds, on protease activity. No significant differences were found for either Ec
ClpP or the Ct ClpP2/P1 in the presence or absence of DMSO.
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Figure 3.3. Assessment of ClpP1 and ClpP2 activity using the fluorescent peptide
assay. 3 µM ClpP1 and ClpP2 were co-incubated with 500 µM Suc-Luc-Tyr-AMC at
37°C for 6 hours with (buffer F) or without (buffer E) 200 mM sodium citrate. Reactions
were monitored using a BioTek Synergy HT plate reader set at an excitation of 340/360
and an emission of 440/460 with readings taken every five minutes. (A and B) Summary
results for ClpPec and ClpP1/P2. Background was subtracted from each sample and
the average values are reported with standard error. N = 3 for Ct ClpP1/P2, n = 2 for Ec
ClpP; two different protein purification preparations were tested. (C and D) Original
curve data averaged from all trials with error bars reported as standard error. Reported
in figure S3 of (55).
The protease data (fig. 3.3) support that our purified ClpP2/P1 have activity and
prior work with ClpP proteins indicates that oligomerization is required for proteolysis.
To confirm that our Ct ClpP1 and ClpP2 proteins form a collaborative complex, nativePAGE gels were run to test for homo-oligomerization of the two heptamers and the
formation of the functional tetradecamer (fig. 3.4). ClpP1 and ClpP2 were incubated
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either alone or together in oligomerization buffer at 37°C to stimulate oligomer formation
followed by complex analysis on native-PAGE. ClpP1 has a monomeric weight of 21
kDa, so the heptamer should be ~147 kDa. ClpP2 has a monomeric weight of 22 kDa,
and heptameric weight of ~154 kDa. Together, the tetradecamer of ClpP1 and ClpP2
should yield a molecular weight of ~301 kDa. Both ClpP1 and ClpP2 formed homoheptameric complexes at the expected molecular weight. When mixed together, they
formed the tetradecamer (arrow) at the expected molecular weight of ~301 kDa (fig.
3.4). The native-PAGE results in conjunction with protease activity of the Ct ClpP1/P2
complex support that our ClpP preparations are functional, which we then leveraged for
studies of activating compounds (fig. 3.5) and for later assessment of ClpX function.

Figure 3.4. Native-PAGE of ClpP1, ClpP2, and ClpP1/ClpP2. 5 µg of ClpP1 and ClpP2
protein was incubated at 37C for 20 minutes. The reaction was mixed with 5X native
sample buffer and analyzed using native-PAGE followed by Coomassie Brilliant Blue
staining. A native MW ladder is on the left of the gel. The arrow is pointing to the heterotetradecamer complex formed by combining ClpP1 and ClpP2. A representative gel is
shown. Reported in figure S2 of (55).
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Investigation of ClpP as a druggable target
Previous researchers have identified small molecule compounds that are toxic to
ClpP-possessing bacteria by stimulating unregulated activity of ClpP. These activators
work by opening the ClpP barrel so it can degrade large substrates that it would not
otherwise be able to degrade on its own without the help of an adaptor protein. Since
the activity of the ClpP1 and ClpP2 complex could be demonstrated using the
fluorescent peptide assay, we could then test our proteins against various activators in a
FITC-casein assay (fig. 3.5). In this assay, the fluorophore FITC is conjugated to casein,
which is a substrate normally too large for the ClpP1 and ClpP2 complex to degrade. In
the presence of activating compounds, the complex should be able to degrade the
FITC-casein, which results in an increase in RFU. The activators, synthesized by the
Martin Conda-Sheridan group at UNMC, were initially tested in vivo against Chlamydia
and a number of compounds caused a decrease in inclusion size, altered inclusion
morphology, and significant reductions in inclusion forming units approaching a 3-log
drop (IFUs) (55). As the activators were designed based on previous drugs that targeted
proteolytic enzymes, we hypothesized that these activators were targeting the ClpP2/P1
complex of Chlamydia. We tested the compounds in vitro using the FTIC-casein assay
using Ec ClpP and Ct ClpP2/P1. Compound 40 had the greatest activation of the
complex with over a 26-fold increase compared to the next highest activators 11 and
then 16 versus the Ec ClpP (fig, 3.5A). Excepting compounds 9 and 11, which showed
modest activation, no activation was detected with the Ct ClpP 2/P1 complex using the
FITC-casein assay (fig. 3.5B), suggesting that these activators were not affecting
chlamydial growth via activation of the ClpP2/P1 complex.
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Figure 3.5. Effect of activating compounds against the Ec ClpP and Ct ClpP1/P2
complexes. Activators were incubated with E. coli ClpP or Ct ClpP2/P1 without FITCcasein for 30 minutes at 32°C. Upon addition of 20 μM FITC-casein, the fluorescence
owning to FITC-casein degradation was measured for three hours with readings every
three minutes. (A) Activators against the Ec ClpP complex. (B) Activators against the Ct
ClpP2/P1 complex. Reported in figure 7 of (55).
ClpX-ClpP2/P1 interactions
After confirming we had functional ClpP1/P2 proteins, we turned our attention to
studies on the protease-adaptor complexes. To dissect different ClpX “jobs” as
highlighted in the introduction, we generated ClpX amino acid mutants with alterations
in a number of task-specific motifs identified through sequence alignment with ClpX
homologs from other bacteria (fig. 3.6). When compared to the ClpX of E. coli, B.
subtilis, Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Staphylococcus
aureus, the Ct ClpX was found to possess key residues for ClpX function including: the
Walker B motif for ATP hydrolysis (mutated E187A), IGF loops to bind to the ClpP
complex (mutated I269E), the RKH motif for the SsrA-degron tag recognition (mutated
R230A), pore 1 loop for substrate translocation from ClpX to the ClpP complex (mutated
V156F), and the zinc-binding domain (ZBD) for binding of adaptor proteins to ClpX
(deleted amino acids 1-64; ClpX adaptor proteins unknown for Chlamydia). Ct ClpX
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retains other important motifs associated with ClpX function as highlighted in fig. 3.6.,
but not confirmed for function in this study. The amino acid mutants constructed and the
expected phenotypes are summarized in table 1.

Figure 3.6. Bioinformatic analysis of chlamydial ClpX supports its role as an AAA+
ATPase. Multiple-sequence alignment of Ct ClpX with the ClpX orthologs of various
other bacteria. Ec, Escherichia coli; Ctr, Chlamydia trachomatis; Bs, Bacillus subtilis;
Mtb, Mycobacterium tuberculosis; Pa, Pseudomonas aeruginosa; Sa, Staphylococcus
aureus. Alignment was performed using Clustal Omega with default settings and
presented using Jalview version 2. Alignment was colored by percent identity in shades
of blue or as indicated below the alignment. Reported in figure 1 of (60).
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Following affinity purification of recombinant wild-type and mutant ClpX proteins,
Native-PAGE gels were used to test for the hexamer formation (fig. 3.7). ClpXwt has a
monomeric molecular weight of 47 kDa and the hexamer should have a molecular
weight of 282 kDa. All of the ClpX mutants, except ClpXΔ1-64, were expected to
migrate at a similar molecular weight as the wild-type since they only have one or two
point mutations. As ClpXΔ1-64 is missing the first sixty-four amino acids, its monomeric
size is 40 kDa and the hexameric complex should migrate at 240 kDa. All ClpX proteins
oligomerized and appeared at their expected molecular weight suggesting that the
proteins purified should be active (fig. 3.7).

Figure 3.7. Native-PAGE of all ClpX clones. Five µg of the different ClpX clones were
incubated at 37C for 20 minutes to promote oligomerization. The reaction was mixed
with 5X native sample buffer and analyzed using native-PAGE. The MW ladder is on the
left of each gel.
As an AAA+ ATPase unfoldase, the adaptor ClpX utilizes ATP to unfold large
substrates that would not otherwise fit in the ClpP2/P1 complex for degradation. Since
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all of the ClpX proteins were able to oligomerize into their functional state on the nativePAGE gels, we assessed the ATPase activity of each clone. We first used a malachite
green-based assay (BioMol) to colorimetrically measure free phosphate released as
ClpX hydrolyzed ATP to ADP (fig. 3.8). ClpX was incubated in ATPase buffer without
ATP for 10 minutes. After addition of ATP, the reaction was incubated for 2 hours at
32°C. After the two hours, BioMol green reagent was added and allowed to incubate at
room temperature for 20 minutes. The release of inorganic phosphate due to ATP
consumption was colorimetrically quantified at Abs620nm. ClpXwt had increased ATP
consumption compared to the ClpX E187A mutant. Since the ClpX E187A mutant had a
mutation in the walker B motif, it was expected to show reduced ability to hydrolyze
ATP. While this assay effectively demonstrated the ATPase activity of ClpX, the small,
although significant, difference in ATP consumption between the ClpXwt and ClpX
E187A mutant along with the variability of the ClpXwt data led us to explore other
approaches (fig. 3.8).
Table 1. List of ClpX mutants and their predicted phenotype.
E187A
Unable to hydrolyze ATP
I269E
Unable to interact with the ClpP1/ClpP2 complex
R230A / E187A Unable to recognize SsrA-tagged substrates / unable to hydrolyze
ATP
V156F / E187A Unable to translocate substrates to the ClpP1/ClpP2 complex /
unable to hydrolyze ATP
I269E / E187A Unable to interact with the ClpP1/ClpP2 complex / unable to
hydrolyze ATP
Δ1-64
Unable to interact with adaptor proteins
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Figure 3.8. ATPase activity of ClpX clones as measured by the BioMol assay.
Recombinant ClpX or mutant ClpX was incubated in ATPase assay buffer without ATP
for 10 minutes at RT. Upon addition of ATP, the reaction was incubated for two hours at
32C. BioMol Green reagent was added to each reaction and then allowed to incubate
for 20 minutes at RT. Inorganic phosphate was colorimetrically quantified at Abs 620nm.
The nmol of inorganic phosphate released was determined using a Pi standard curve.
Error bars are standard deviation and the samples were tested at least three times with
two independent protein purifications. Samples with no significant difference have the
same letter and those with significant difference have different letters.
We next tested the kinase-GLO assay (fig. 3.9), which was expected to be more
sensitive compared to the BioMol assay (fig. 3.8). ClpX and its various mutants were
incubated in ATPase assay buffer without ATP for 10 minutes at room temperature.
Once ATP was added, the reaction was allowed to incubate for 1.5 hours at 30°C and
then for 30 minutes at room temperature. Upon addition of the kinase-GLO reagent, the
level of ATP left in the reaction was measured as relative luminescence (RLU). If a
protein is actively degrading ATP, then the luminescence of the reaction should be
reduced compared to the “ATP only” control sample. ClpXwt, ClpX I269E, and ClpX Δ164 all demonstrated significant ATPase activity compared to the ATP only control. All
other clones containing the E187A Walker B motif mutation showed little to no ATPase
activity. The ATPase activity of ClpX is associated with the Walker A (ATP binding) and
Walker B (ATP hydrolysis) motifs in the protein. The E187A mutation is in the Walker B
motif, so all ClpX clones containing this mutation are still able to bind ATP, but are
45

unable to efficiently hydrolyze it. Although the clones with the E187A mutation were
slightly decreased as compared to the “ATP only” sample, the difference is not
significant. The kinase-GLO ATPase assay was more sensitive than the malachite
green BioMol assay for demonstrating the differential ATPase activity of the various
ClpX clones (figs. 3.9 vs 3.8).

Figure 3.9. ATPase activity of ClpX clones as measured by the kinase-GLO assay.
Recombinant ClpX or mutant ClpX was incubated in ATPase assay buffer without ATP
for 10 minutes at RT. ATP was added to the reaction and incubated at 30C for 1.5
hours. After the 1.5 hours, the reactions were incubated for an additional 30 minutes at
room temperature. Kinase-GLO reagent was added to the reaction and it was incubated
for 10 minutes at RT. The luminescence of the reaction (ATP not consumed by ClpX)
was measured. Reactions were performed in duplicate at least three times with at least
two independent protein preparations. Error bars report standard deviation. Samples
with no significant difference have the same letter and those with significant difference
have different letters.
As our previous assays demonstrated ClpP1/ClpP2 and ClpX activity
independently, we next used the SsrA-tagged GFP degradation assay to measure
proteolysis activity of the ClpX/P2/P1 complex (fig. 3.10). If the complex is able to
recognize and degrade the SsrA-tagged GFP, then there should be a decrease in
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fluorescence owing to degradation of GFP. ClpP1, ClpP2, and ClpX were incubated
with creatine phosphokinase, ATP, and creatine phosphate for 30 minutes at 32°C. The
creatine components were added as an ATP regeneration system, which proved
essential for the assay. SsrA-tagged GFP was added to the reaction and the
degradation of GFP or lack thereof was measured over two hours. ClpXwt and ClpX Δ164 were the only clones to demonstrate proteolysis activity, although the ClpX Δ1-64
showed reduced kinetics and lower overall activity than the ClpX wt. ClpX I269E
carrying a mutation in the (I/L/V)-G-(F/L) motif (IGF loops) that is essential for
interaction with the ClpP1/ClpP2 complex did not show any degradation of ATP. All
other ClpX mutants have the E187A mutation, leading to reduced ATP hydrolysis and
subsequent reduced degradation of the degron-tagged GFP.
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Figure 3.10. SsrA-tagged GFP degradation by the ClpXP complex. ClpP1, ClpP2, and
ClpX were incubated with ATP, creatine-phosphate, 10X buffer PZ, and creatine
phosphokinase for 30 minutes at 32C. GFP was then added to the reaction and
fluorescence was read for two hours at excitation λ = 465 nm and emission λ = 535 nm.
Reactions were performed in duplicate at least three times with at least two independent
protein preparations. (A) Percent change in GFP degradation with standard deviation.
Samples with no significant difference have the same letter and those with significant
difference have different letters. (B) Original curve data averaged from all trials with
error bars reported as standard deviation.
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ClpCP / McsAB
We hypothesize that the adaptor ClpC can also function with the ClpP2/P1
complex at the ClpP1 interface and that ClpC will be able to recognize and degrade
proteins that have been phosphoarginine-tagged by McsAB. We speculate that tagging
could be important for stress responses and developmental transitions. Based on the
system in B. subtilis, McsA would act as the activator of the arginine kinase McsB and
together they would be able to deliver doomed proteins to the ClpCP complex. We
performed bioinformatic analysis of the Ct McsA and McsB to determine their similarity
to the McsA and McsB proteins more typically found in gram positive bacteria. NCBI
BLASTP was used to identify Mcs-homologs and multiple-sequence alignments were
performed using MUltiple Sequence Comparison by Log- Expectation (MUSCLE) with
default settings and edited using BioEdit. In fig. 3.11A, Ct McsA was compared against
four other bacteria: Chlamydia pneumoniae (Cpn), Staphylococcus epidermidis (Sep),
B. subtilis (Bs), and Geobacillus stearothermophilus (Gst). All McsA proteins contained
a conserved UvrB/UvrC motif, which is associated with protein-protein interactions (69,
70). The Ct McsA retains all conserved cysteine residues (highlighted in blue) and
shares an additional cysteine with its close neighbor C. pneumoniae (highlighted in
green). As the EB (oxidized) and RB (reduced) have differing redox statuses, the high
cysteine content of Ct McsA may have relevance for regulating McsA activity. Cysteines
that are highlighted red (fig. 3.11A) and circled in red (fig. 3.11B) are those that were
mutated for in vivo studies and will be further mentioned in the discussion. The
sequence alignment and annotation suggests that the Ct McsA is similar to those of
other bacteria and is likely to function as an activator of the partner McsB. Ct McsB was
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also compared to the McsB proteins from the same organisms. Highlighted are motifs
associated with McsB proteins: an ADP binding site (yellow), a phosphagen binding site
(red), and substrate specificity loop (blue) as shown in fig. 3.11B. The sequencing
alignment and annotation suggests that the Ct McsB is similar to those of other bacteria
and would seem supportive of its role as an arginine kinase.
A

B
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Figure 3.11. Bioinformatic analysis of the chlamydial McsA and McsB. Pairwise
alignments were performed using NCBI BLASTP. The multiple-sequence alignment was
performed using MUSCLE with default settings and edited using BioEdit. Organisms
included are C. trachomatis (Ctr), Chlamydia pneumoniae (Cpn), Staphylococcus
epidermidis (Sep), B. subtilis (Bs), and Geobacillus stearothermophilus (Gst).
Conserved residues are highlighted. Black represents strongly conserved identical
residues and gray represents partially conserved or similar residues. (A) Alignment of
McsA. Red indicates cysteine residues mutated in vivo, blue indicates conserved
cysteine residues across all organisms aligned, green indicates extra cysteines found
only in Chlamydia species, and yellow indicates the conserved UvrB/UvrC motif found in
McsA proteins. A percent identity matrix is listed underneath the alignment. (B)
Predicted structure of Ct McsA. The structure was created using Phyre2. (C) Alignment
of McsB. All highlighted regions indicate motifs conserved across all organisms aligned.
Yellow indicates the ADP binding site, red indicates the phosphagen binding site, and
blue indicates the substrate specificity loop for substrate binding. A percent identity
matrix is listed underneath the alignments in A and C.
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Optimization of conditions for purifying Ct/Bs McsA and Ct/Bs McsB
Since ClpP1, ClpP2, and ClpC can already be successfully purified (fig. 3.2), we
focused on determining purification conditions for McsA and McsB. Previously, it was
shown that co-expression of McsA and McsB from different plasmids in the same E. coli
strain could rescue expression of McsB, possibly due to the predicted partnership of the
two proteins (Michelle Malysa, Fisher lab; data not shown). However, it did not correlate
with an increase in solubility for either partner. Therefore, Ct McsA and McsB were
cloned into the two-gene expression plasmid pACYCDuet-1 to normalize expression
levels to each other during co-expression as the cloning sites are encoded in an operon.
After transformation into E. coli BL21 (DE3), each clone was tested for solubility in
different lysis buffers. Cultures were then induced with varying amounts of IPTG and
induced at different times and temperatures. Cell pellets were suspended in lysis buffers
and sonicated to release soluble protein. Samples taken during the protein solubility
trials were then assessed on SDS-PAGE and protein detected with Coomassie Brilliant
Blue staining. While McsA was generally well expressed under conditions tested,
solubility was poor (see example in fig. 3.12A). For McsB, all conditions tested for the
pACYCDuet-1 clone with only mcsB exhibited both poor induction and solubility (fig.
3.12B). Rescue of McsB expression was seen when co-expressing McsA and McsB,
but solubility was still too low to initiate purification (fig. 3.12C).
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Figure 3.12. Representative SDS-PAGE gels of solubility trials for Ct McsA and McsB
from the pACYCDuet-1 vector. The MW ladder is to the left of each gel. The first lane of
each gel represents cultures prior to induction (Pre), the second lane represents
cultures after induction (Post), the third lane represents the non-soluble protein fraction
(NS), and the fourth lane represents the soluble protein fraction (S). (A) pACYCDuet-1
McsA alone, (B) pACYCDuet-1 McsB alone, and (C) pACYCDuet-1 McsA and McsB
together. Expected protein molecular weights in kDa are: 21 kDa for McsA and 42 kDa
for McsB.
The only condition for the pACYCDuet-1 McsA that demonstrated promising
purification conditions was 1 mM IPTG for 10 hours at 37°C using the pACYCDuet-1
buffers listed in Appendix B. A 50 mL culture of pACYCDuet-1 mcsA strain was grown
to an OD600nm between 0.6-0.8, induced, and then spun down for storage overnight. The
next day, McsA was purified via IMAC using HisPur Cobalt Resin. McsA was
concentrated and stored in its storage buffer (Appendix B), quantified using the Bradford
assay, and assessed on SDS-PAGE. Figure 3.13B is the quality control protein
purification gel used to assess if the purification was successful or not. Although protein
induction was strong, there was not a comparable amount of soluble protein as seen in
the solubility trial gel in fig. 3.13A. This led to very little protein in the elution fractions
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and a very dilute, unusable protein product. Based on the data in fig. 3.13B, we decided
to pursue other approaches for purifying McsA.
A

B

Figure 3.13. pACYCDuet-1 mcsA expression vector solubility trial and purification. (A)
The boxed protein band represents the soluble McsA protein using the pACYCDuet-1
McsA lysis buffer. (B) The 6xHis-tagged McsA was purified via IMAC using HisPur
Cobalt Resin.
Since the pACYCDuet-1 clones did not yield sufficient levels of soluble protein,
the proteins were next cloned into pLATE31 to generate C-terminal 6xHis-tagged
proteins. The advantage of this vector is the previous successes seen with the other
purified Clp proteins (fig. 3.2). However, this system would not allow co-expression of
McsA and McsB in a single protein expression strain from the same vector although
they could be transformed into the pACYCDuet-1 strain containing the other Mcs protein
as seen in fig. 3.12. Ct McsA and McsB were induced for 2.5 hours at 37°C so they
could be tested for basic expression via α-His western blot (fig. 3.14A). Following
confirmation of expression, pLATE31 mcsB was transformed into the strain carrying
pACYCDuet-1 mcsA to test if this method of co-expression would be successful in
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rescuing McsB expression as previously seen in fig. 3.12. Unfortunately, expression and
solubility of both proteins was still suboptimal (fig. 3.14B).
A

B

Figure 3.14. α-His western of from the pLATE31 mcsA and mcsB strains and a
representative solubility trial for the pLATE31 mcsB/pACYCDuet-1 mcsA co-expression
strain. (A) Left is the SDS-PAGE gel with the corresponding western blot on the right.
(B) Co-expression solubility trial. The first lane of the gel represents the culture prior to
induction (pre), the second lane represents the culture after induction (post), the third
lane represents the non-soluble protein fraction (NS), and the fourth lane represents the
soluble protein fraction (S). Expected product sizes in kDa are: 21 kDa for McsA and 42
kDa for McsB.
Since solubility was poor using the different combinations of pACYCDuet-1 and
pLATE31 vectors, clones containing new vectors and tags were created. Ct mcsA and
mcsB were cloned into pGex-6p-1 and pMAL-c5X vectors via restriction digestion and
transformed into the E. coli ΔPAX strain. Cultures were grown to an OD600nm of 0.6-0.8
and induced with 1 mM IPTG for 2.5 hours at 37°C. After being spun down and stored
overnight, samples were resuspended in McsA lysis buffer, sonicated, and assessed for
protein production on 10% SDS-PAGE gels. The strain with pMAL-c5X mcsA produced
an abundance of soluble protein (fig. 3.15A). Neither of the pGex-6p-1 vectors nor the
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pMAL-c5X containing mcsB were able to produce soluble protein in the lysis buffers
tested (fig. 3.15B).
While the solubility profile of MBP-McsA was positive, a disadvantage of the
MBP-construct was that MBP is a large tag at 42 kDa compared to the size of Ct McsA
at 21 kDa. Since the MBP tag could interfere with the activity of McsA in future activity
assays, an optimal MBP-tag cleavage protocol was determined (fig. 3.15C). After
purification, the MBP-tagged McsA was subject to various tag cleavage conditions using
factor Xa to determine optimal tag cleavage. Optimal cleavage was determined to be at
room temperature for 24 hours as seen in fig. 3.15C. Compared to the control, almost
all of the MBP-tagged McsA was cleaved into its separate parts of MBP and McsA
alone, although McsA was buried in the dye front (arrow) due to the low percentage
SDS-PAGE gel used. Ct McsA could now be successfully purified and the MBP tag
cleaved in case it interfered in future activity assays.
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Figure 3.15. pGex-6p-1 and pMAL-c5X Ct mcsA and mcsB strain solubility trials and
MBP-tag cleavage from MBP-McsA. SDS-PAGE gels of (A) McsA, (B) McsB, and (C)
24 hours at RT MBP-tag cleavage of McsA using factor Xa. Cleaved McsA is buried in
the dye front represented by the arrow. Markers are shown to the left of each gel.
Expected protein sizes for the pGex-6p-1 clones are: 46 kDa for McsA and 67 kDa for
McsB. Expected protein sizes for the pMAL-c5x clones are: 63 kDa for McsA and 83
kDa for McsB.
Since many different conditions and tags tested in E. coli still did not yield a
condition in which Ct McsB could be purified, a new expression system using B. subtilis
was tested. This system was chosen because the McsAB system is an almost
exclusively gram positive system, so perhaps E. coli is just unable to express Ct McsB
at high levels and prior work by Suskiewicz et al. reported some toxicity when
expressing McsB from B. subtilis in E. coli (71). Another reason for the switch was that
as the system is most well-characterized in B. subtilis, we could purify and use Bs McsA
and McsB as controls in future activity assays. Ct McsA/B and Bs McsA/B were PCR
amplified from the respective genomic DNA of each organisms and cloned into the E.
coli, B. subtilis shuttle vector pHT08 (fig. 3.16). The pHT08 vector is from the Pgrac01
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expression system and has a C-terminally encoded 8xHis-tag. Based on the initial
vector publication, upon IPTG induction the tagged protein should account for 10-13%
of the total cellular protein (Bacillus subtilis Pgrac01 Expression Vectors manual from
MoBiTec).
A

B

Figure 3.16. Amplification of Ct and Bs mcsA and mcsB from the respective gDNA. (A)
mcsA and mcsB amplified from Ct L2 gDNA. (B) mcsA and mcsB amplified from Bs 168
gDNA. PCR products were run on an agarose gel and DNA visualized with ethidium
bromide staining followed by UV transillumination.
After the Ct mcsA/B and Bs mcsA/B clones were created and transformed into B.
subtilis, protein expression was assessed. Protein expression was first tested with the
Ct gene clones. Upon growth to an OD600nm between 0.6-0.8, cultures were induced
with 1 mM IPTG for 2.5 hours at 37°C. Previous work in E. coli utilized Laemmli buffer to
visualize proteins on SDS-PAGE. However, when Laemmli was used with B. subtilis,
little to no protein was seen on the SDS-PAGE gel (fig. 3.17A). Two different methods of
B. subtilis sample preparation were then tested. The first and selected method is
described in the materials and methods. The second method lysis buffer (50 mM Tris
[pH 7.2], 15% w/v sucrose, 2.5 mg/mL lysozyme) and 3X sample buffer (135 mM Tris,
30% glycerol, 3% w/v SDS, 150 mM DTT, and 0.03% bromophenol blue) were not
effective and showed streaking on the SDS-PAGE gels as seen in fig. 3.17B and C.
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Figure 3.17. B. subtilis sample lysis experiments. (A) SDS-PAGE with the pre- and
post-induction samples of Ct McsA and McsB lysed using Laemmli. (B) McsA sample
lysis using method one and two. (C) McsB sample lysis using method one and two.
Method one was selected for further use.
Prior to testing for optimal induction and solubility conditions, post-induction
samples of Ct McsA and McsB were subject to an α-His western to determine if they
were being expressed in B. subtilis. Westerns were done using a mouse monoclonal α6xHis antibody and a goat anti-mouse IgG HRP conjugated secondary antibody. As
shown in fig. 3.18B, neither Ct McsA nor McsB were detected. However, this same blot
was reprobed using mouse α-Ct McsA antibody (provided by Dr. Gaungming Zhong, UT
San Antonio) and Ct McsA was detected at the expected molecular weight of 21 kDa
(fig. 3.18C). Although a band appeared just above the expected molecular weight of Ct
McsB (42 kDa), this was suspected to be non-specific binding of the antibody since it
was present in both lanes.
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Figure 3.18. α-His and α-McsA western blots of Ct McsA. (A) Coomassie Brilliant Blue
stained SDS-PAGE control for western showing total protein. (B) α-His western blot of
Ct McsA and McsB. (C) α-His western blot was reprobed with α-McsA.
Failure of the α-His western blot could have been due to at least three reasons:
1) the His tag of the pHT08 vector was not exposed in my Ct proteins, 2) the α-6xHis
antibody could not bind to an 8xHis tag although there was no evidence from other
studies to suggest this would be a problem, or 3) the western failed as a bona-fide Histagged positive control protein was not run in the previous western in fig. 3.18B. To
trouble-shoot the anti-His western blotting, the pre-induction and post-induction samples
from Ct McsA, Bs McsA, and the post-induction sample of a previous ClpX purification
were used. ClpX has a 6xHis-tag that had been previously detected by our antibody, but
the 6xHis-tag would not allow us to rule out that the α-6xHis antibody is unable to bind
to an 8xHis tag. Again, the α-6xHis antibody did not detect the Ct McsA or Bs McsA (fig.
3.19). However, the α-6xHis antibody was able to detect the positive control ClpX, so
the failure of the western could be due to reason one or two as stated above. Reason
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one would be problematic because if the tag is buried in the protein, then the His-Pur
cobalt resin would also fail to bind to the tagged proteins, so purification via IMAC would
not be possible.

Figure 3.19. α-His western blot of Ct McsA, Bs McsA, and ClpX. Left is the Coomassie
Brilliant Blue stained SDS-PAGE control for the western and right is the western blot.
Protein sizes should be 21 kDa for Bs McsA, 21 kDa for Ct McsA, and 47 kDa for ClpX.
Although the α-His western blots failed, the α-McsA western blot was successful
in detecting the pHT08-expressed Ct McsA, so further induction trials were performed
for McsA without continued trouble-shooting for detection. Since Ct McsB could not be
detected, induction trials were performed in tandem with Ct McsA to see if the Ct McsB
could be visually confirmed using Coomassie Brilliant Blue staining under more optimal
induction conditions. Fifty mL cultures were grown to an OD 600nm between 0.6-0.8 in
2xYT media and then split into 5 mL aliquots that received either 0.1, 0.5, or 1 mM IPTG
and were incubated for either 3 hours at 37°C, 10 hours at 37°C, or 20 hours at 18°C.
Samples were assessed on 12% SDS-PAGE gels (fig. 3.20). Arrows represent the
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expected location of each protein. For both proteins, there were no obvious changes in
expression levels despite the altered induction conditions. These gels did not support
the hypothesis that expression of Ct McsA and McsB in a B. subtilis expression system
would provide better expression, so a new method of expression would be needed to
obtain improved yields and soluble protein.
A

B

Figure 3.20. Induction trials of Ct McsA and McsB. Cultures were induced with either
0.1, 0.5, or 1 mM IPTG for either 3 hours at 37°C, 10 hours at 37°C, or 20 hours at 18°C
Coomassie Brilliant Blue stained SDS-PAGE gels of (A) Ct McsA and (B) Ct McsB.
To improve upon expression and solubility, we assessed codon bias as a reason
for poor protein expression and solubility. Both sequences were codon optimized for
expression in either E. coli or B. subtilis using codon optimization tools provided by
NovoPro and Integrated DNA Technologies (IDT). NovoPro provided graphs showing
the improvement of sequences upon optimization, and the graphs were used to further
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optimize sequences by hand. A representative graph of Ct McsA optimization for
expression in E. coli is shown in fig. 3.21. Codons that fell below 10% of relative
adaptiveness were replaced with codons that had ≥20% of relative adaptiveness as
determined by NovoPro. Examples of the improvement of relative adaptiveness is
shown with arrows. After creation of optimized Ct McsA and McsB sequences for E. coli
or B. subtilis, the respective gBlocks were ordered and cloned into protein expression
strains of E. coli using pLATE52 or B. subtilis using pHT08.

Figure 3.21. Representative codon optimization plot. Graphs were generated using the
codon optimization tool offered by NovoPro. Similar colored arrows represent examples
of codons that were corrected and the increase in percentage of relative adaptiveness.
The pLATE52 clones containing the codon optimized gBlocks of Ct McsA (g52A)
and McsB (g52B) were cloned and transformed into the E. coli ΔPAX strain for protein
expression. Fifty mL cultures of g52A and g52B were grown to an OD 600nm of 0.6-0.8
and induced with 1 mM IPTG for 2.5 hours at 37°C. Post-induction samples were taken
and run on a 12% SDS-PAGE gel (fig. 3.22). The Coomassie Brilliant Blue stained
SDS-PAGE gel showed the largest post-induction band seen thus far for McsB (except
when co-expressed in the pACYCDuet-1 vector with mcsA as seen in fig. 3.12C). We
attempted to confirm expression of both of the codon-optimized McsA and McsB
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proteins via western blot with the mouse monoclonal α-6xHis antibody. Both the ClpX
positive control and McsA were successfully visualized on the western blot, but McsB
was not seen despite the prominent band observed on the Coomassie Brilliant Blue
stained SDS-PAGE.

Figure 3.22. α-His western blot of McsA and McsB samples expressed from the codon
optimized genes. Left is the Coomassie Brilliant Blue stained SDS-PAGE control for the
western blot and on the right is the western blot with ClpX as a positive control.
Since previous α-His western blots to confirm expression of Ct McsB (fig. 3.21)
and proteins expressed from B. subtilis (figures 3.18 and 3.19) failed, a urea denaturing
purification was attempted. The advantage of this method is that even if the tag is buried
in the native protein as previously suspected, the urea would denature the proteins so
the HisPur cobalt resin would have access to the His tag on the proteins so they could
be purified. The disadvantage of the urea approach is that the proteins are denatured so
they cannot be used directly in activity assays. Fifteen mL cultures of g52B and pHT08
strains containing the codon optimized gBlocks of Ct McsA (g08A) and Ct McsB (g08B),
and Bs McsA/B were grown to an OD600nm of 0.6-0.8 and then induced with 1 mM IPTG
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for 2.5 hours at 37°C. Cultures were spun down after induction and stored overnight at
-80°C. The next day, cultures were purified via IMAC using HisPur cobalt resin. Preinduction, post-induction, soluble, post-bind, elution, and resin samples from the
purification were assessed on 12% SDS-PAGE gels and visualized using Coomassie
Brilliant Blue staining (fig. 3.23). For g52B, a large amount of 6xHis-tagged McsB was
recovered on the resin, thus supporting that the g52B clone was being expressed in E.
coli and was ready for induction and solubility trials. For the proteins expressed in B.
subtilis (p08B), there was significantly less protein recovered as seen on the g52B gel.
However, there was enough protein recovered on the resin fractions for each protein
(arrows) to support that the proteins were being expressed in B. subtilis. The urea
denaturing purification demonstrated that the g52B, g08A/B, and Bs A/B expression
strains were producing enough protein to initiate testing of optimal induction and
solubility conditions.
A

B

C

Figure 3.23. Urea denaturing purification SDS-PAGE gels for protein expressed from
the g52B, g08 A/B, and Bs A/B strains. (A) g52B, (B) g08A and g08B, and (C) Bs A and
B denaturing purification gels. Arrows point out the protein recovered from the HisPur
Cobalt Resin.
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After confirmation that the gBlock codon optimized pLATE52 McsA and McsB
were being expressed (figs. 3.22 and 3.23A), induction trials were conducted to
determine the optimal IPTG concentration and induction time and temperature. Fifty mL
cultures of each strain were grown to an OD600nm of 0.6-0.8, split into 15 mL aliquots,
and induced with either 0.1, 0.5, or 1 mM IPTG at either 37°C for 2.5 hours, room
temperature for 6 hours, or 18°C for 20 hours. After the induction time, post-induction
samples were taken for assessment on SDS-PAGE via Coomassie Brilliant Blue
staining. For both McsA and McsB, the strength of the band increased as induction time
increased. Based on the gels in fig. 3.24, the optimal induction condition for both
proteins was determined to be 0.5 mM IPTG for 20 hours at 18°C.
A

B

Figure 3.24. Induction trials of g52A and B. Cultures were induced with either 0.1, 0.5,
or 1 mM IPTG for either 2.5 hours at 37°C, 6 hours at RT, or 20 hours at 18°C. (A) g52A
and (B) g52B induction trials. Arrows represent the chosen induction condition.
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After determining that 18°C for 20 hours with 0.5 mM IPTG was the optimal
induction condition, different lysis buffers were tested to determine optimal solubility.
Figure 3.25 shows representative gels based on solubility trials with these clones. In this
study, optimal solubility conditions were not able to be determined for either McsA or
McsB despite trying various different lysis buffer conditions.
A

B

Figure 3.25. Representative gels of g52 A and B solubility trials. The first lane of each
gel represents cultures prior to induction, the second lane represents cultures after
induction, the third lane represents the non-soluble protein fraction, and the fourth lane
represents the soluble protein fraction. (A) g52A and (B) g52B solubility trial SDS-PAGE
gels.
Following confirmation that Bs McsA and McsB were being expressed in B.
subtilis (fig. 3.23C), induction trials were performed to determine optimal IPTG induction
concentration, temperature, and length of time. Fifty mL cultures of each strain were
grown to an OD600nm of 0.6-0.8, split into 15 mL aliquots and induced with either 0.1,
0.5, or 1 mM IPTG at either 37°C for 2.5 hours, room temperature for 6 hours, or 18°C
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for 20 hours. After induction, cultures were lysed using urea lysis buffer and IMAC resin
was used to pull the induced protein out of the supernatant for assessment on SDSPAGE (fig. 3.26). Without this extra step, it would be difficult to determine the optimal
induction condition because as is seen in fig. 3.23C, the proteins were difficult to detect
in the post-induction samples. Bs McsA had a similar induction band across all
conditions tested. Bs McsB had the strongest induction band at 37°C for 2.5 hours with
1 mM IPTG. Since the induction condition impacted Bs McsB expression, but not Bs
McsA, the optimal induction condition for both proteins was chosen to be 37°C for 2.5
hours with 1 mM IPTG guided by the results for Bs McsB.
A

B

Figure 3.26. Induction trials of Bs McsA and McsB. Cultures were induced with either
0.1, 0.5, or 1 mM IPTG for either 2.5 hours at 37°C, 6 hours at RT, or 20 hours at 18°C.
(A) Bs A and (B) Bs B induction trials. Arrows represent the chosen induction condition.
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McsA Thermotolerance Growth Assay
In parallel with our attempts to express soluble Ct McsA and McsB in both E. coli
and B. subtilis, we attempted to establish an in vivo assay that would establish
functionality via complementation of a B. subtilis 168 ΔmcsA mutant with the Ct mcsA.
Since the McsAB system is used in response to heat stress in B. subtilis, strains were
grown at 53°C to test for complementation of the heat resistance phenotype (fig. 3.27).
The B. subtilis strain expressing Bs McsA grew similarly to the WT strain supporting
complementation although there was a slightly extended lag phase of the Bs McsA
strain in the presence of IPTG. IPTG has been reported to cause growth delays when
added to a culture in the lag phase (72). For Ct McsA without IPTG, the strain grew the
same as the B. subtilis 168 ΔmcsA. However, the Ct McsA with IPTG strain grew
moderately quicker, although it was still much slower in comparison to the WT and Bs
McsA complemented strain. In conclusion, the expression of Ct McsA in B. subtilis does
not improve thermotolerance.

Figure 3.27. Thermotolerance Assay of Bs and Ct McsA. Cultures were grown with
shaking for eight hours in a 53°C water bath with or without IPTG. OD 600nm readings
taken every hour. The experiment was performed for eight hours and error bars report
two independent experiments.
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CHAPTER 4
DISCUSSION AND CONCLUSION
C. trachomatis is the most commonly reported cause of bacterial sexually
transmitted infections in the United States and is the leading cause of preventable
blindness worldwide. Although antibiotic resistance is not a current clinical problem for
chlamydial infections, the occurrence of asymptomatic infections that can lead to
complications including pelvic inflammatory disease and infertility coupled with drug
treatment failure emphasizes the need for a vaccine or specialized treatment options. In
addition, since infections are currently treated with broad spectrum antibiotics, it would
be preferred to find specific therapeutic targets in Chlamydia that would decrease the
incident of treatment failure and prevent induction of dysbiosis and the development of
non-chlamydial drug-resistance (14).
As Chlamydia undergo a biphasic developmental cycle between two distinct
forms (fig. 1.1) with unique protein profiles that presumably promote growth, replication,
and survival from host innate and adaptive immune response stressors, mechanisms
that regulate proteostasis are likely essential for survival in the host. The Clp systems
are a highly conserved system that functions in proteostasis by removing unwanted,
damaged, denatured, and aberrantly folded proteins that are harmful to the cell. Due to
the importance of the Clp systems for normal growth and stress responses, they have
been targets for drug development as novel approaches for treatment of bacterial
infections (54, 73). Chlamydia spp. encode two adaptor Clp components, ClpX and
ClpC, two protease components, ClpP1 and ClpP2, and protease targeting components
McsA and McsB (fig. 3.1). The maintenance of multiple clp genes in a minimal genome
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organism suggests a critical role for the genes in promoting chlamydial fitness. In vivo
support for the importance of the Clp system for chlamydial growth and development
comes from our collaborative work showing that the expression of catalytically impaired
forms of ClpP1 and ClpX or CRISPRi mediated knockdown of ClpP2 and ClpX
significantly reduces chlamydial fitness (40, 60). These results support targeting the
chlamydial Clp components as a therapeutic approach.
Typically, the ClpP drugs used are more effective against gram positive bacteria
than gram negative bacteria due to permeability problems with the gram negative
envelop making them narrow spectrum compounds (54). Our in vivo studies reported
reduced chlamydial growth with ClpP-activators (55). While our in vitro data (fig. 3.5) are
inconclusive regarding the mechanism of action of these compounds in vivo, the cell
culture assays indicate that ClpP-drugs have potent anti-chlamydial properties. Our in
vitro results also confirm that modification of the drugs can result in differential activity
towards ClpPs from different species including E. coli (fig. 3.5A) and the human and
mouse mitochondrial ClpP homolog (data not shown, reported in (55)). These data
support that the Clp system could be leveraged to make a Chlamydia-specific drug.
To facilitate drug development and to better define the function of the Clp system
in chlamydial growth, we sought to characterize the individual chlamydial Clp
components and to reassemble the proteins into active complexes as required for drug
testing and Clp-substrate identification. The latter point would be informative for
selecting which components are the best druggable candidates for inhibiting bacterial
growth. Based on prior studies with other Clp systems and work done on the chlamydial
system as an undergraduate before initiating my thesis, we hypothesized that: 1) these
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systems are essential for chlamydial development, 2) the ClpX/P2/P1 system will be
important for degradation of proteins produced by trans-translation, and 3) the
ClpC/P1/P2 and McsAB system will degrade phosphoarginine tagged proteins and will
aid in redox signaling in Chlamydia. While not all of these hypotheses could be directly
tested during my thesis, we are better positioned to perform this work in the near future.
ClpX/P2/P1
The ClpXP system can serve various functions in cells. A common function of
ClpXP is degrading tagged proteins produced by trans-translation, which we
hypothesized would also be one of its functions in Chlamydia which possess the transtranslation components (74). Before addressing its role in Chlamydia, we first sought to
characterize the different components of the ClpX/P2/P1 system in Chlamydia. Based
on work by both us and Pan et al. (48), the current model of the ClpX/P2/P1 system in
Chlamydia is that the two ClpP paralogs, ClpP1 and ClpP2, form homo-heptamers that
come together to form a functional hetero-tetradecamer protease (fig. 3.1B). This
ClpP2/P1 complex alone can degrade smaller substrates, such as seen in the
fluorescent peptide degradation assay (fig. 3.3), but upon association with the unfoldase
ClpX, the system can recognize larger and specifically tagged substrates (fig. 3.10).
Based upon the genomic organization, we hypothesized that ClpX will interact with the
ClpP2 interface of the complex (fig. 3.1A). Although this question was not specifically
pursued in this study, work by Pan et al. supports this hypothesis (48). In addition to the
basic ClpX/P2/P1 system, we hypothesized based on other bacterial ClpXP systems
and the presence of the ZBD motif (fig. 3.6) that the chlamydial ClpX will be able to work
with different adaptor proteins to alter what ClpP2/P1 is able to degrade. One such
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example is of the single domain response regulator CpdR and the phosphodiesterase
PdeA involved in Caulobacter crescentus cell cycle regulation. Dephosphorylation of
CpdR leads to degradation of PdeA by its ClpXP complex to help facilitate the transition
between the dimorphic forms of C. crescentus (62, 75). Although adaptor proteins were
not examined in this study, we hypothesize that their interaction with the chlamydial
ClpX/P2/P1 system will be essential for its development and will be an interesting area
of future study. To enable such studies, we purified and performed initial
characterization of the Δ1-64 ClpX mutant that lacks the ZBD motif and should have
reduced interactions with adaptor proteins. We confirmed that the protein could still
oligomerize, hydrolyze ATP, and degrade an SsrA-tagged substrate (figs. 3.7, 3.9, and
3.10). Expression of this mutant protein in C. trachomatis by our collaborators will help
to discern how important other adaptor proteins are towards ClpX function.
To enable for rigorous characterization of the chlamydial ClpX/P2/P1 system in
vitro, we successfully purified ClpP1, ClpP2, ClpX, and various ClpX mutants in addition
to ClpP from E. coli for use as a control protein (fig. 3.2). We also purified an SsrAtagged GFP to test as a substrate of the system. To test for activity of the ClpP2/P1
complex, we utilized the Suc-Luc-Tyr-AMC fluorescent peptide degradation assay. The
E. coli ClpP was highly active compared to the chlamydial version (fig. 3.5). On nativePAGE, ClpPec preferentially forms its active tetradecamer (40) as compared to the
ClpP1 and ClpP2 of Chlamydia that preferentially forms its inactive heptamers, so this
may explain the large differences in activity seen in this assay under the conditions
tested. Nonetheless, ClpP2/P1 were able to degrade the peptide, and this effect was
significantly increased upon the addition of sodium citrate which promotes
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oligomerization. We further confirmed P1/P2 interactions using native-PAGE (fig. 3.4).
Distinct lower bands in the P1/P2 mixed lane that were at the same size of the
oligomers in the ClpP1 and ClpP2 only lanes suggested that the proteins are only able
to form homo-heptamers, and not hetero-heptamers as can be seen in some species of
cyanobacteria that express ClpP1 and ClpP2 homologs (76).
As work with other bacteria encoding ClpP suggested that drug-induced
hyperactivation of ClpP reduced growth, our collaborators at UNMC tested existing and
modified versions of ClpP activators against C. trachomatis in vivo (55). We then tested
a limited number of the compounds, guided by in vivo data, on the ClpP2/P1 complex in
vitro using the FITC-casein degradation assay (55). A number of the compounds led to
a decrease in inclusion size, altered inclusion morphology, and reduced IFUs. Based on
prior literature, we hypothesized that the decreased chlamydial growth observed was
due to activation of the ClpP2/P1 complex. However, no significant activation was seen
with any of the activators when used against the ClpP2/P1 complex using the in vitro
FITC-casein assay (fig. 3.5), suggesting that these activators might not be acting
through alteration of the ClpP complex activity. Activation was seen with certain
compounds when used with the ClpP of E. coli, so the FITC-casein degradation assay
will still be useful in testing future activating compounds. Although we hypothesized that
these compounds would activate the ClpP complex, the negative data for the FITCcasein assay led us to test the compounds in the fluorescent peptide degradation assay
for ClpP inhibition, which was not observed (data not shown). The fluorescent peptide
degradation assay could be used to test for inhibitory compounds against the ClpP2/P1
complex since a decrease in activity could be determined, especially when used in the
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presence of sodium citrate. The FITC-casein degradation assay would not be useful for
testing inhibitors because ClpP2/P1 without an adaptor cannot degrade FITC-casein as
seen in the DMSO control. Future work should also test compounds in the GFP
degradation assay to assess inhibition in a configuration that is a better physiological
mimic of what would occur in vivo. Taken altogether, the ClpP2/P1 complex of
Chlamydia is functional in vitro when tested for fluorescent peptide degradation and
when tested for oligomerization using the native-PAGE assay.
Before characterizing the chlamydial ClpX/P2/P1 system as whole, we sought to
examine and characterize the motifs and activity of the unfoldase ClpX. When
compared to the amino acid sequences of ClpX of five other bacteria, the chlamydial
ClpX retained many conserved motifs (fig. 3.6). The following motifs are those that were
mutated and examined for function in this study. Near the N-terminus, the chlamydial
ClpX retains the ZBD needed to bind to adaptor proteins that enables the ClpP2/P1
complex to differentially degrade substrates as previously stated. ClpX also retains the
Walker A and Walker B motifs needed for binding and hydrolysis of ATP, respectively.
Conservation of this motif is essential since ClpX utilizes ATP to unfold large substrates
that would not otherwise be degraded by the ClpP2/P1 complex. The chlamydial ClpX
also retains IGF loops that enable binding to the ClpP2/P1 complex, an RKH motif for
SsrA-tag recognition, and a pore 1 loop for substrate translocation from ClpX to the
ClpP2/P1 complex. Regardless of the mutations mentioned here, we hypothesized that
the ClpX proteins should be able to oligomerize into their functional hexamer and
hexamer oligomerization was seen with every ClpX construct (fig. 3.7). Since the ClpX
clones could all oligomerize, the ATPase activity of each was tested. The Malachite
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Green BioMol Assay was initially use to measure the difference in release of inorganic
phosphate due to ATP consumption between the wild-type and Walker B mutant ClpX
(fig. 3.8). However, the small although significant difference in ATP consumption and
the variability of the ClpXwt data was concerning because such a small difference
becomes a problem when testing for the differential activity of ClpX mutants or of
inhibitors or activators towards ClpX. Therefore, measurement of ATPase activity of the
ClpX clones was switched over to the more sensitive kinase GLO assay. All ClpX
clones containing the Walker B mutation had reduced ability to hydrolyze ATP as
expected (fig. 3.9). The ClpXwt and ClpX I269E clones similarly utilized ATP; however,
the ClpX Δ1-64 clone had increased ATP hydrolysis as compared to the wild-type. This
result was not unexpected based on work by (59).
Since the activities of the ClpP2/P1 complex and ClpX could be demonstrated
separately, we next confirmed that the protease complex and adaptor protein would
work together. The SsrA-tagged GFP degradation assay was effective in demonstrating
that the ClpX/P2/P1 system was functional (fig. 3.10). We also assessed whether a
mutated SsrA-tag (VAA to VDD) would be ignored by ClpX as a negative control and
obtained the expected result of a degradation-resistant GFP (data not shown). The
ClpXwt protein had the highest rate of degradation and percent difference as compared
to all other constructs tested. The ClpX Δ1-64 clones was also able to degrade GFP,
however its rate of degradation was slower as compared to the wild-type. A previous
study suggested that although ClpX Δ1-64 can still degrade SsrA-tagged GFP, its drop
in efficiency as compared to the wild-type may suggest that the ZBD has some
importance in the unfoldase activity because of a secondary binding site present in the
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ZBD for the GFP-SsrA (59). As expected, no other constructs were able to degrade
GFP: ClpX I269E due to its inability to bind to the ClpP2/P1 complex and all of the
double mutants containing the Walker B motif mutation due to their inability to utilize
ATP to linearize GFP for degradation in the protease complex. Inability of the I269E
mutant to form the hetero-complex with ClpP2/P1 as suggested by lack of activity in the
GFP assay should be further confirmed through the ATPase assay whereby ATP
hydrolysis would remain unchanged in the presence of ClpP2/P1. Addition of the
protease components typically reduces ATPase activity of ClpX unless a substrate is
present (77). Complex formation could also be assessed using native-PAGE or gel
filtration chromatography.
Unfortunately, single mutant constructs of R230A (inability to recognize SsrA-tag)
and V156F (inability to translocate substrates to the ClpP2/P1 complex) were not
created in time to be tested and included in this study. The R230A mutant should not
engage the SsrA tag and will be helpful for assessing the importance of non-SsrA
functions when expressed in vivo while the V156F mutant should not be able to
translocate substrates into the ClpP2/P1 complex. The latter should be confirmed in the
GFP degradation assay and this translocation mutant should be useful for identify ClpX
substrates in vivo by functioning as a “substrate trap” that binds, but does not degrade
substrates. While the single mutants were not tested, we hypothesize that they will
generate similar results to their double mutant partners. Overall, our data demonstrates
a functional ClpX/P2/P1 complex in vitro and the first characterization of conserved
motifs in the chlamydial ClpX.
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As our study mainly focuses on the in vitro characterization of the chlamydial
ClpX/P2/P1 system, efforts to identify other substrates and adaptor proteins will be done
in vivo by the Ouellette group at UNMC. Upon identification of other adaptors or
substrates, it will be important to test these substrates in degradation assays to both
further elucidate motif activity in ClpX and to confirm if identified proteins really are
substrates of the ClpX/P2/P1 system. Labelling of substrate proteins with FITC as done
for the casein assay (fig. 3.5) or simple Coomassie Brilliant Blue staining of SDS-PAGE
resolved degradation products (55) should allow for analysis of degradation of bona-fide
substrates. Further work will also be needed to identify specific activators (or inhibitors)
due to previous failures to demonstrate activation of the ClpP2/P1 complex. However,
we did identify and validated in vivo an inhibitor of ClpX/SsrA-mediated degradation that
led to a significant reduction in chlamydial fitness further supporting the Clp system as a
druggable target (60). Overall, basic characterization of the ClpX/P2/P1 system has
shown that it functions in a similar manner to other ClpXP systems, although we predict
that additional activities of the ClpX/P2/P1 system specific to Chlamydia are present
and future work will be needed to test this hypothesis. In support of chlamydial specific
functions, the mentioned ClpX inhibitor and overexpression of ClpX mutants led to an
RB to EB developmental defect in a cell culture infection model (60).
ClpCP / McsAB
In B. subtilis, where this system is most well characterized, the ClpCP / McsAB
system functions in the degradation of phosphoarginine-tagged proteins. Although it is
an almost exclusively gram positive system, we hypothesize that it will function in a
similar manner in Chlamydia, which is gram negative. The ClpC/P1/P2 complex should
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function similarly to the ClpX/P2/P1 system in that the ClpP2/P1 complex serves as the
proteolytic component and ClpC functions in unfolding and linearizing substrates in an
ATP-dependent manner. Since we previously hypothesized that ClpX binds to the
ClpP2 interface, we hypothesize that ClpC will bind to the ClpP1 interface, although this
was not pursued in our study. In B. subtilis, McsA acts as the activator of the arginine
kinase McsB and together they deliver doomed proteins to the ClpCP complex. Since
gram negative bacteria do not have the McsAB system, we performed bioinformatic
analysis of the chlamydial McsA and McsB to further test their assignments as
homologous to the McsA and McsB proteins seen in gram positive bacteria (fig. 3.11).
All McsA proteins contained a conserved UvrB/UvrC motif, which is associated with
protein-protein interactions. The UvrABC endonuclease of E. coli is involved in excision
repair of damaged nucleotides in DNA, but proteins UvrB and UvrC utilize this specific
motif to interact with and activate each other and we predict this motif in McsA allows it
to form either homo or hetero oligomers (70). When using MUSCLE to align the
UvrB/UvrC motifs against the respective McsB of Chlamydia and B. subtilis, neither
motif in the McsA proteins aligned with regions in the McsB proteins, suggesting that
this motif in McsA may function in dimerization of McsA or interaction with other proteins
in the cell. The Ct McsA retains all conserved cysteine residues and shares an
additional cysteine with its close neighbor C. pneumoniae that is absent from the other
bacteria assessed. Although we are unsure of the function of the “extra” cysteine
residues, we hypothesize based on other McsA homologs that the conserved cysteines
will function as redox-sensitive activators of McsB. In Chlamydia’s developmental cycle,
EBs are generally oxidized while RBs are generally reduced. In the case of McsA, we
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predict it will be inactive while oxidized (thus inactivating McsB) and active while
reduced. Although no in vitro data was collected on the function of redox on McsA, in
vivo our collaborator constructed a triple AxxA mutant in the conserved cysteine
residues 11/14, 64/66, and 83/85 (highlighted in red on fig. 3.11A and circled in fig.
3.11B) in McsA and expressed it during infection. They demonstrated a lack of staining
for an EB-associated marker HctB in the triple mutant expressing strain at the same
time point where abundant HctB was detected in the wild-type strain. The results
suggest a delay in progression through the developmental cycle in the presence of the
redox insensitive McsA. Future work for McsA in relation to its role in redox signaling
should be addressed both in vitro and in vivo. A click-PEG redox labelling system (78)
to test the redox status of McsA as Chlamydia progresses through the development
cycle would be informative and one could use the click-PEG system either in vitro or in
vivo to discern which cysteines are oxidized and when oxidation occurs. The click-PEG
system works by alkylating a reduced thiol with propargyl-maleimide and then
conjugating it with an azide-PEG of high molecular weight (e.g. 5kDa) using coppercatalyzed Click chemistry leading to altered migration of labeled protein on SDS-PAGE.
Two other potentially interesting aspects of the chlamydial McsA as compared to the
other aligned McsA proteins are a missing stretch of 19 amino acids between ~80-100
(on the ruler on fig. 3.11A) and the insertion of 9 amino acids between positions ~135145.
McsB proteins typically retain three conserved motifs (fig. 3.11C). First, the ADP
binding site that enables ATP to be a phosphate donor, which corresponds with the
activation of McsB via phosphorylation (as seen in the B. subtilis McsAB model). The
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second motif is the phosphagen binding site. To satisfy short-term energy requirements,
broadly classified, phosphagen kinases can catalyze the reversible transfer of a
phosphate from phosphorylated guanidine molecules such as phosphoarginine or
phosphocreatine to ADP. We hypothesize that the chlamydial McsB functions as an
arginine kinase and has homology with the phosphagen kinases/phosphagen binding
site owing to the similar mechanism of action and phosphorylation substrates used by
both phosphagen kinases and arginine kinases. Finally, all of the McsB proteins share
the substrate specificity loop for substrate binding. However, it should be noted that Ct
McsB it is missing some key residues associated with other bacterial arginine kinases
(71). While this does not exclude the chlamydial McsB from being an arginine kinase, it
will be critical to confirm activity and to test if it can phosphorylate other residues instead
or in addition to arginine.
To begin characterization of the chlamydial ClpC/P2/P1 / McsAB system in vitro,
we first needed purified protein. Since ClpP1, ClpP2, and ClpC could already be
purified, conditions for purification of McsA and McsB were the focus of Aim 2 of the
thesis. For McsA, the only condition tested that produced soluble protein that could be
purified was MBP-tagged McsA from the pMAL-c5X vector. Despite codon optimization
and use of B. subtilis as an expression system, we were unable to generate soluble
McsA that encoded a tag smaller than that of MBP. However, codon optimization of
McsA and expression in E. coli produced promising induction trials for a His-tagged
version, so solubility trials of this protein should still be pursued (fig. 3.24). If future
attempts to produce soluble codon optimized McsA still fail, an optimal procedure to
cleave the MBP tag from McsA has already been determined, so McsA alone could be
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used in future activity assays. Removal of the MBP tag may prove critical as the large
tag could interfere with McsA function by blocking protein-protein interactions.
Since we were unable to test McsA in an in vitro assay due to the inability to get
purified McsB, we attempted a thermotolerance assay using both the Bs McsA as a
control and Ct McsA since the McsAB system is used during the heat stress response in
B. subtilis. Both the wild-type 168 and Bs McsA – IPTG grew at the same rate, with the
Bs McsA + IPTG lagging slightly behind (fig. 3.27). This slight lag could just be due to
adding IPTG at the start of growing the culture, which has been shown to cause a delay
in growth (72). The Bs 168 ΔmcsA and Ct McsA – IPTG both grew at the same rate,
while the Ct McsA + IPTG grew slightly faster. While the result of the Ct McsA + IPTG
might suggest some complementation of the B. subtilis McsAB system, we were unable
to determine a condition in which the Ct McsA complemented strain grew similarly to
any of the strains containing the Bs McsA. Two potential explanations for this include: 1)
the Ct McsA is not able to complement the Bs McsAB system or 2) there may not be
complementation because the assay was done at 53°C, but Chlamydia typically grow at
37°C so the Ct McsA is simply unable to function at that high of a temperature.
Therefore, a different complementation assay that does not include a high temperature
condition such as transformation efficiency via natural competence should be
attempted. For McsB, none of the conditions tested produced soluble protein that could
be purified. However, codon optimized McsB produced the best induction condition
seen throughout this entire study (fig. 3.24), so despite initial failures to get soluble
protein, it should still be pursued for solubility and purification by varying lysis
conditions.
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In conclusion, our work has set the stage for more detailed characterization of
the Clp system both in vitro and in vivo. We can now purify all components except McsB
using E. coli as a surrogate host and have established assays to measure Clp functions
including oligomerization, ATP hydrolysis (shown for ClpX, applicable to ClpC), and
various degradation assays. Our assay “toolbox” will be critical for teasing apart the
roles of different Clp-conserved motifs in Clp complex function and for the development
of chlamydial-specific Clp-inhibitors and activators. In addition, our combined in vitro
and in vivo data also highlight the critical role of the Clp system in chlamydial fitness
and development, further supporting the system as a therapeutic target and its
importance for chlamydial proteostasis.
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APPENDIX A
E. COLI AND B. SUBTILIS STRAINS WITH PLASMID, ANTIBIOTIC RESISTANCE,
AND DESCRIPTION
Clone

pLATE31 clpX I269E
pLATE31 clpX R230A/E187A
pLATE31 clpX V165F/E187A
pLATE31 clpX Δ1-64
pLATE31 clpX I269E/E187A
pLATE31 clpPec

Background
strain
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli DH5α
E. coli DH5α
E. coli DH5α
E. coli DH5α
E. coli DH5α
E. coli ΔPAX

pLATE31 clpP1

E. coli ΔPAX

pLATE31 clpP2

E. coli ΔPAX

pLATE31 clpC

E. coli ΔPAX

pLATE31 clpX

E. coli ΔPAX

pLATE31 clpX E187A

E. coli ΔPAX

pLATE31 clpPec
pLATE31 clpP1
pLATE31 clpP2
pLATE31 clpC
pLATE31 clpX
pLATE31 clpX E187A
pLATE31 clpPec
pLATE31 clpP1
pLATE31 clpP2
pLATE31 clpC
pLATE31 clpX
pLATE31 clpX E187A
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Resistance
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan

Description
Cloning
Cloning
Cloning
Cloning
Cloning
Cloning
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Cloning
Cloning
Cloning
Cloning
Cloning
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression

pLATE31 clpX I269E

E. coli ΔPAX

pLATE31 clpX R230A/E187A

E. coli ΔPAX

pLATE31 clpX V165F/E187A

E. coli ΔPAX

pLATE31 clpX Δ1-64

E. coli ΔPAX

pLATE31 clpX I269E/E187A

E. coli ΔPAX

pGex-6p-1 gfp VAA full

pGex-6p-1 gfp VAA full

E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli ΔPAX

pGex-6p-1 gfp VAA truncated

E. coli ΔPAX

pGex-6p-1 gfp VDD full

E. coli ΔPAX

pGex-6p-1 gfp VDD truncated

E. coli ΔPAX

pLATE52 gfp VAA full
pLATE52 gfp VAA truncated
pLATE52 gfp VDD full
pLATE52 gfp VDD truncated
pLATE52 gfp VAA full

E. coli DH5α
E. coli DH5α
E. coli DH5α
E. coli DH5α
E. coli ΔPAX

pLATE52 gfp VAA truncated

E. coli ΔPAX

pLATE52 gfp VDD full

E. coli ΔPAX

pGex-6p-1 gfp VAA truncated
pGex-6p-1 gfp VDD full
pGex-6p-1 gfp VDD truncated
pGex-6p-1 gfp VAA full
pGex-6p-1 gfp VAA truncated
pGex-6p-1 gfp VDD full
pGex-6p-1 gfp VDD truncated
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Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp

Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Cloning

Amp

Cloning

Amp

Cloning

Amp

Cloning

Amp

Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Cloning
Cloning
Cloning
Cloning
Protein
expression
Protein
expression
Protein
expression

Amp
Amp
Amp
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp
Amp
Amp
Amp
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan

pLATE52 gfp VDD truncated

E. coli ΔPAX

pACYCDuet-1 Ct mcsA
pACYCDuet-1 Ct mcsB
pACYCDuet-1 Ct mcsA and mcsB
pLATE 31 mcsA
pLATE 31 mcsB
pLATE 31 mcsB and pACYCDuet-1
Ct mcsA
pACYCDuet-1 Ct mcsA

pGex-6p-1 Ct mcsA
pGex-6p-1 Ct mcsB
pMAL-c5X Ct mcsB
pMAL-c5X Ct mcsA
pGex-6p-1 Ct mcsA

E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli BL21
(DE3)
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli XL-1 Blue
E. coli ΔPAX

pGex-6p-1 Ct mcsB

E. coli ΔPAX

pMAL-c5X Ct mcsA

E. coli ΔPAX

pMAL-c5X Ct mcsB

E. coli ΔPAX

pHT08
pHT08

E. coli DH5α
B. subtilis 168

pHT08 Ct mcsA
pHT08 Ct mcsB
pHT08 Ct mcsA

E. coli DH5α
E. coli DH5α
B. subtilis 168
ΔmcsA
B. subtilis 168
ΔmcsA
B. subtilis 168
ΔmcsB
B. subtilis 168
ΔmcsB

pACYCDuet-1 Ct mcsB
pACYCDuet-1 Ct mcsA and mcsB
pLATE 31 mcsA
pLATE 31 mcsB

pHT08
pHT08 Ct mcsB
pHT08
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Amp, cm,
kan
Cm
Cm
Cm
Amp
Amp
Cm and
amp
Cm
Cm
Cm
Amp
Amp
Amp
Amp
Amp
Amp
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp, cm,
kan
Amp
Cm
Amp
Amp
Cm, kan
Cm, kan
Cm, kan
Cm, kan

Protein
expression
Cloning
Cloning
Cloning
Cloning
Cloning
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Cloning
Cloning
Cloning
Cloning
Protein
expression
Protein
expression
Protein
expression
Protein
expression
Cloning
Protein
expression
Cloning
Cloning
Protein
expression
Protein
expression
Protein
expression
Protein
expression

pHT08 Bs mcsA
pHT08 Bs mcsB
pHT08 Bs mcsA
pHT08 Bs mcsB
pLATE52 codon opt. gBlock of Ct
mcsA
pLATE52 codon opt. gBlock of Ct
mcsB
pLATE52 codon opt. gBlock of Ct
mcsA
pLATE52 codon opt. gBlock of Ct
mcsB
pHT08 codon opt. gBlock of Ct
mcsA
pHT08 codon opt. gBlock of Ct
mcsB
pHT08 codon opt. gBlock of Ct
mcsA
pHT08 codon opt. gBlock of Ct
mcsB

E. coli DH5α
E. coli DH5α
B. subtilis 168
ΔmcsA
B. subtilis 168
ΔmcsB
E. coli DH5α

Amp
Amp
Cm, kan

Amp

Cloning
Cloning
Protein
expression
Protein
expression
Cloning

E. coli DH5α

Amp

Cloning

E. coli ΔPAX

E. coli DH5α

Amp, cm,
kan
Amp, cm,
kan
Amp

Protein
expression
Protein
expression
Cloning

E. coli DH5α

Amp

Cloning

B. subtilis 168
ΔmcsA
B. subtilis 168
ΔmcsB

Cm, kan

Protein
expression
Protein
expression

E. coli ΔPAX
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Cm, kan

Cm, kan

APPENDIX B
BUFFER LIST
Buffer
ClpP lysis / wash buffer
ClpP elution buffer
ClpP storage buffer
ClpX lysis / wash buffer
ClpX elution buffer
ATPase assay buffer
GFP lysis buffer
GFP wash buffer
GFP elution buffer
GFP storage buffer
pACYCDuet-1 McsA lysis
buffer
pACYCDuet-1 McsA wash
buffer
pACYCDuet-1 McsA elution
buffer
pACYCDuet-1 McsA storage
buffer
McsA lysis buffer

Components
25 mM Tris Base [pH 7.5], 150 mM NaCl, 10 mM
Imidazole, 10% glycerol
25 mM Tris Base [pH 7.5], 150 mM NaCl, 300 mM
Imidazole, 10% glycerol
25 mM Tris Base [pH 7.5], 150 mM NaCl,10% glycerol
25 mM Tris Base [pH 7.5], 300 mM NaCl, 10 mM
Imidazole
25 mM Tris Base [pH 7.5], 300 mM NaCl, 300 mM
Imidazole
25 mM HEPES [pH 7.2], 200 mM KCl, 20 mM MgCl 2,
10% glycerol
50 mM NaH2PO4 [pH 8], 300 mM NaCl, 20 mM
Imidazole, protease inhibitor
50 mM NaH2PO4 [pH 8], 300 mM NaCl, 20 mM
Imidazole
50 mM NaH2PO4 [pH 8], 300 mM NaCl, 300 mM
Imidazole
50 mM NaH2PO4 [pH 8], 300 mM NaCl, 10% glycerol
50 mM NaH2PO4 [pH 7.8], 300 mM NaCl, 10 mM
Imidazole, 0.1% Triton X-100, 10% glycerol, 1 mg/mL
lysozyme, protease inhibitor
50 mM NaH2PO4 [pH 7.8], 300 mM NaCl, 10 mM
Imidazole, 0.1% Triton X-100, 10% glycerol
50 mM NaH2PO4 [pH 7.8], 300 mM NaCl, 300 mM
Imidazole, 0.1% Triton X-100, 10% glycerol
20 mM HEPES [pH 7.4], 200 mM KCl, 10% glycerol

McsA storage buffer

50 mM NaH2PO4 [pH 7.8], 300 mM NaCl, 10 mM
Imidazole, 0.1% Triton X-100, 10% glycerol, 1 mM
DTT, 1 mg/mL lysozyme, protease inhibitor
50 mM NaH2PO4 [pH 7.8], 300 mM NaCl, 10 mM
Imidazole, 0.1% Triton X-100, 10% glycerol, 1 mM
DTT
50 mM NaH2PO4 [pH 7.8], 300 mM NaCl, 1 mM DTT,
10 mM maltose, 10% glycerol
50 mM NaH2PO4 [pH 7.8], 300 mM NaCl, 10% glycerol

Cleavage buffer
Buffer E

20 mM Tris-HCl [pH 8], 100 mM NaCl, 2 mM CaCl2
50 mM Tris-HCl [pH 8], 200 mM KCl, 1 mM DTT

McsA wash buffer
McsA elution buffer
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Buffer F
Buffer PZ
Oligomerization Buffer
Native Running Buffer
Native Sample Buffer
2xYT medium*
10X S-base*
HS medium*#

LS medium*#

Bacillus subtilis
Electroporation Buffer*
Bacillus subtilis
Electroporation Recovery
Buffer*#
Bacillus subtilis 5X SDS
Lysis Buffer
Bacillus subtilis SDS Sample
Buffer
Urea Lysis Buffer

50 mM Tris-HCl [pH 8], 200 mM KCl, 1 mM DTT, 200
mM trisodium citrate
25 mM HEPES [pH 7.6], 200 mM KCl, 5 mM MgCl2, 1
mM DTT, 10% glycerol
25 mM Tris Base [pH 7.5], 5 mM KCl, 5 mM MgCl2, 1
mM DTT, 10% glycerol
30 g Tris base, 144 g glycine, dH2O to 1 L
5 mM Tris [pH 6.8], 38 mM glycine, 0.06%
bromophenol blue
2xYT: in 500 mL  8 g tryptone, 5 g yeast extract, 2.5
g NaCl
2 g (NH4)2SO4, 14 g K2HPO4, 6 g KH2PO4, 1 g sodium
citrate, add ddH2O to 100 mL and autoclave, add 0.1
mL of filter sterilized 1 M MgSO4
66.5 mL ddH2O, 10 mL 10X S-base, 2.5 mL 20%
glucose, 5 mL 0.1% L-tryptophan, 1 mL 2% casamino
acids, 5 mL 10% yeast extract, 10 mL 8% arginine /
0.4% histidine
80 mL ddH2O, 10 mL 10X S-base, 2.5 mL 20%
glucose, 0.5 mL 0.1% L-tryptophan, 0.5 mL 2%
casamino acids, 5 mL 2% yeast extract, 0.25 mL of 1
M MgCl2, 0.05 mL of 1 M CaCl2
0.5 M trehalose, 0.5 M sorbitol, 0.5 M mannitol, 0.5
mM MgCl2, 0.5 mM K2HPO4, pH 7.4, molecular grade
water
2xYT broth containing 0.5 M sorbitol and 0.38 M
mannitol
20 mM Tris, 15% w/v sucrose

50 mM Tris [pH 6.8], 100 mM DTT, 30% v/v glycerol,
10% w/v SDS, 0.02% Bromophenol Blue
50 mM Tris [pH 7.4], 7 M Urea, 300 mM NaCl, 10 mM
Imidazole
Urea Elution Buffer
50 mM Tris [pH 7.4], 7 M Urea, 300 mM NaCl, 150 mM
Imidazole
*Bacillus subtilis Pgrac01 Expression Vectors manual from MoBiTec
#Autoclave all components separately then combine, filter sterilize L-tryptophan
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APPENDIX C
PRIMER LIST
Vector / Insert
pLATE31 clpPec
F
pLATE31 clpPec
R
pLATE31 clpP1
F
pLATE31 clpP1
R
pLATE31 clpP2
F
pLATE31 clpP2
R
pLATE31 clpC F
pLATE31 clpC R
pLATE31 clpX F
pLATE31 clpX R
pLATE31 clpX
Δ1-64 F
pLATE52 gfp F
pLATE52 gfp
VAA full R
pLATE52 gfp
VAA trunc R
pLATE52 gfp
VDD full R
pLATE52 gfp
VDD trunc R
pGex-6p-1 gfp F
pGex-6p-1 gfp
VAA full R
pGex-6p-1 gfp
VAA trunc R
pGex-6p-1 gfp
VDD full R
pGex-6p-1 gfp
VDD trunc R

Sequence (5'-3')
AGAAGGAGATATAACTATGTCATACAGCGGCGAACGAG
GTGGTGGTGATGGTGATGGCCATTACGATGGGTCAGAATCG
AATCG
AGAAGGAGATATAACTATGCCTGAAGGGGAAATGATGCATAA
G
GTGGTGGTGATGGTGATGGCCCAAGTCGTTAAAAGAGAAGA
GAATCCC
AGAAGGAGATATAACTATGACGTTGGTACCATACGTTGTTGAA
G
GTGGTGGTGATGGTGATGGCCAGACGCAATACTCTTATCTTT
TGTC
AGAAGGAGATATAACTATGTTTGAGAAGTTTACCAATCGCGCA
AAGCAAG
GTGGTGGTGATGGTGATGGCCTGATTCATCAGCTGTAATAG
AGAAGGAGATATAACTATGACAAAAAAAAATCTTGCGGTCTGT
TC
GTGGTGGTGATGGTGATGGCCAGCAATCGCCTCTGGTGATTT
C
AGAAGGAGATATAACTATGAGAGTGTTAACCCCTAAAG
GGTTGGGAATTGCAAAGTAAAGGAGAAGCACTTTTCACTGGA
G
GGAGATGGGAAGTCATTATTAAGCAGCTACGCGTAGATC
GGAGATGGGAAGTCATTATTAAGCAGCTACCTTGTATAGTTCA
TC
GGAGATGGGAAGTCATTATTAATCATCTACGCGTAGATCTTC
GAGATC
GGAGATGGGAAGTCATTATTAATCATCTACCTTGTATAGTTCA
TCCATGC
CTGGGATCCAGTAAAGGAGAAGCACTTTTCAC
AACCGGCCGTTAAGCAGCTACGCGTAGATCTTCG
CGAGTCGACTTAAGCAGCTACCTTGTATAGTTCATCCATG
AACCGGCCGTTAATCATCTACGCGTAGATCTTCG
CGAGTCGACTTAATCATCTACCTTGTATAGTTCATCCATGCCA
TGTGTAATC
95

pLATE31 mcsB
F
pLATE31 mcsB
R
pLATE31 mcsA
F
pLATE31 mcsA
R
pGex-6p-1 mcsA
F
pGex-6p-1 mcsA
R
pGex-6p-1 mcsB
F
pGex-6p-1 mcsB
R
pMAL-c5X mcsA
F
pMAL-c5X mcsA
R
pMAL-c5X mcsB
F
pMAL-c5X mcsB
R
pACYCDuet-1
mcsA F
pACYCDuet-1
mcsA R
pACYCDuet-1
mcsB F
pACYCDuet-1
mcsB R
pHT08
sequencing
primer F
pHT08
sequencing
primer R
pHT08 Ct mcsA
F
pHT08 Ct mcsA
R
pHT08 Ct mcsB
F
pHT08 Ct mcsB
R

AGAAGGAGATATAACTATGCTCCCTAATCATATTCTTAC
GTGGTGGTGATGGTGATGGCCGATTCGAATAATCAGTCGCTC
TGCC
AGAAGGAGATATAACTATGGATCATACAGAAGAGTCTCCTGC
TCTTTG
GTGGTGGTGATGGTGATGGCCGGGAGCATCGGTAGTATTCT
G
CTGGGATCCGATCATACAGAAGAGTCTCCTGCTCTTTG
CCGCTCGAGTCAGGGAGCATCGGTAGTATTC
CTGGGATCCCTCCCTAATCATATTCTTAC
CCGCTCGAGTCAGATTCGAATAATCAGTCG
TGGGCGGCCGCGATCATACAGAAGAGTCTCCTGCTCTTTG
TTCGGATCCTCAGGGAGCATCGGTAGTATTC
TGGGCGGCCGCCTCCCTAATCATATTCTTACTGC
TTCGGATCCTCAGATTCGAATAATCAG
CCAGGATCCAGATCATACAGAAGAGTCTCCTGCTCTTTG
TATGCGGCCGCTTAGGGAGCATCGGTAGTATTC
ATACATATGCTCCCTAATCATATTCTTACTGCTATC
AGACTCGAGGATTCGAATAATCAGTCGCTC
CCTCGTTTCCACCGGAATTAGCTTG
GCCGATATTAGCCTCGTATG
CACGGATCCGATCATACAGAAGAGTCTCCTGCTCTTTG
TGCCCCGGGTTAGGGAGCATCGGTAGTATTCTG
CACGGATCCCTCCCTAATCATATTCTTACTGCTATCG
TGCCCCGGGTTAGATTCGAATAATCAGTCGCTCTGCCTGG
96

pHT08 Bs mcsA
F
pHT08 Bs mcsA
R
pHT08 Bs mcsB
F
pHT08 Bs mcsB
R
Codon opt.
pLATE52 Ct
mcsA F
Codon opt.
pLATE52 Ct
mcsA R
Codon opt.
pLATE52 Ct
mcsB F
Codon opt.
pLATE52 Ct
mcsB R

CACGGATCCTTGATTTGTCAAGAGTGCCACGAGAG
TGCCCCGGGTTACTCCTGTTCCTCCTCACTATC
CACGGATCCTCGCTAAAGCATTTTATTCAG
TGCCCCGGGTCATATCGATTCATCCTCCTGTC
CGGTTGGGAATTGCAAGATCACACCGAGGAATCTCCTGCTCT
G
CGGAGATGGGAAGTCATTAAGGGGCATCGGTCGTGTTCTGG
TCCGGTTGGGAATTGCAACTGCCGAACCACATCCTG
CGGAGATGGGAAGTCATTAGATGCGGATGATCAGACG
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